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ABSTRACT 
 
 
Objectives:  Despite the common use of off-label prescribing in the US, no research has been 
conducted to understand the impact of off-label prescribing on patient decision making.  This 
study sought to measure the impact on trust in physicians, intentions of involvement in the 
decision making, beliefs about the drug, and initial compliance intentions in elderly and 
nonelderly populations.    
 
Methods:  This study was designed to assess the effects of off-label prescribing using a 2 × 2 × 2 
design.  Using an online panel, 830 consumers were surveyed, 409 elderly and 421 nonelderly, 
using 8 different scenarios based on disease criticality, off-label use norms, and the FDA 
approval status of the drug for the disease for which it was prescribed. The effect on trust in the 
physician, intentions of involvement in decision making, beliefs about the drug, and initial 
compliance intentions were assessed.    
 
Results:  Off-label prescribing decreased trust in the physician, increased intentions of 
involvement in medical decision making, and lowered positive beliefs about the drug.  There was 
a greater loss in physician trust when receiving an off-label prescription in a less critical disease 
state than when receiving an off-label prescription in a more critical disease state.  The data 
revealed a significant loss in positive beliefs about the drug when receiving an off-label 
prescription compared to on-label drug in the less critical disease state.  Respondents judged the 
physician-provided information about the drug as relevant/reliable, and this led to the creation of 
 iii 
positive beliefs about the drug as well as initial compliance intentions.  The elderly appeared 
slightly more trusting of physicians and positive in their beliefs about drugs and possessed higher 
intentions of initial compliance.   
 
Conclusions:  Off-label prescribing can lead to deleterious effects on patients’ health, including 
lower compliance, lower trust in the physician, and lower beliefs in the drug.  Differences exist 
between the elderly and the nonelderly that may call for different interventions.  As shown in 
previous research, judgments of the relevance/reliability of the information appear to filter which 
information is used to form beliefs about the drug and affect initial compliance intentions.  This 
work revealed a rich area for future research. 
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CHAPTER I 
INTRODUCTION 
 
Off-label prescribing is the use of a prescribed medication in a manner different from that 
approved by the Food and Drug Administration (FDA) (Stafford 2008).  In the United States, 
since 1962, a prescription drug must be proven safe and effective for the indications listed on its 
label before it is approved for marketing.  Former FDA Acting Director Steven Galson stated the 
following about an FDA approval and its associated safety and efficacy:   
What it means when a drug is approved is that the risks are outweighed by the benefits 
for the indication and under the conditions that are in the label.  That just means if the 
drug is used in the right patients, in the right way, at the right dose, and there aren’t drugs 
that are contraindicated taken with it, that the benefits outweigh the risks.  There’s a lot 
that can go wrong that doesn’t fit under that definition.  But the benefits outweigh the 
risks for the indication and under the conditions of use that we specify when we approve 
drugs, and the public should feel very comfortable with the review process.  (PBS 2011) 
Once a product is approved by the FDA and marketed in the United States, however, 
physicians can legally rely on their professional judgment to use an FDA-approved product in 
different diseases, different aged patients, or different doses that are not approved by the FDA.  
This is called off-label use.  Examples are: 
 Different disease – an FDA-approved drug to treat blood pressure is used to treat 
migraine headaches 
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 Different patients – an FDA-approved drug to treat depression is used in children less 
than 12 years of age even though it was not studied in this population 
 Different dose – an FDA-approved drug to treat a sinus infection is used at a higher 
dose than listed in the FDA-approved label. 
The FDA even condones off-label use when appropriate: 
Good medical practice and the best interests of the patient require that physicians use 
legally available drugs, biologics and devices according to their best knowledge and 
judgement.  If physicians use a product for an indication not in the approved labeling, 
they have the responsibility to be well informed about the product, to base its use on firm 
scientific rationale and on sound medical evidence, and to maintain records of the 
product’s use and effects.  (FDA 2011) 
Off-label prescribing is rather common, especially in the therapeutic areas of oncology, 
psychiatry, HIV, and pediatrics (Radley et al. 2006, Peppercorn 2008, Soares 2005, Tarbarrok 
2000, Bazzano 2009, Pathak et al. 2010).  One study found that 80% of oncologists had used 
drugs off-label and approximately half of their chemotherapy use was for indications not 
approved by the FDA (Mortenson 1988).  Despite the common occurrence of off-label 
prescribing, there are no US studies addressing patient attitudes or behaviors toward prescriber 
behavior that may significantly affect patient health.  Only the opinions of parents of 51 healthy 
children and 43 children with renal disease (Lenk et al. 2009) have been assessed in Germany.  
“Knowledge about the practise of off-label use [was] generally poor in both groups.  
Surprisingly, this [was] also true for the parents of children with chronic disease.  Nine percent 
of the parents of chronically ill children and 20% of the parents of healthy children would refuse 
treatment with an off-label drug” (p. 1743). 
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Although it is legal in the US for physicians to use drugs off-label, it is not legal for drug 
companies to market FDA-approved drugs for off-label uses.  Numerous legal cases against 
companies promoting prescription drugs off-label have resulted in billions of dollars in 
settlements and fines (examples include Pfizer’s settlement for $2.3 billion in 2009 after Eli Lilly 
was charged $1.4 billion earlier that year) (Law 2007).  Off-label marketing is very different 
from off-label use, and this study does not address implications of off-label marketing. 
The use of off-label drugs has been addressed from the viewpoints of the physician, 
payer, regulatory, and legal communities.  However, a void exists in the literature for studies 
assessing US patients’ attitudes toward off-label use, the perceived value of an approved FDA 
indication, and the patient decision making to comply with the physicians’ prescribing of off-
label drugs. 
 
Medication Compliance/Adherence 
Compliance is defined as the extent to which a patient takes the medication as prescribed 
by the health care provider.  The term has been criticized because it suggests that patient 
involvement is passive.  Adherence is also used as it suggests the addition of patient agreement 
with the instructions (Osterberg and Blaschke 2005, Bentley et al. 1999).  
Patients can deviate from the prescriber’s instructions either volitionally or 
nonvolitionally.  When the patient makes a conscious choice to be noncompliant with the 
instructions is involved, the deviation is volitional (Bentley et al. 1999).     
The exact path of noncompliance is rather complex, and the costs are potentially greater 
than $258.3 billion (Express Scripts 2010).  After a review of the literature (1966 to 2002) on 
compliance among community-dwelling older patients, Vik et al. (2004, p. 303) found that 
“polypharmacy and poor patient–healthcare provider relationships (including the use of multiple 
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providers) may be major determinants of nonadherence among older persons, with the impact of 
most sociodemographic factors being negligible.  There is little consensus regarding other 
determinants of nonadherence.”  The authors also report that as high as 11% of hospitalizations 
among older patients are attributable to nonadherence (Vik et al. 2004).   
 
Patient Decision Making 
Patient decision making is complex.  Fincham and Wertheimer (1985) identified more 
than 250 social, economic, medical, and behavioral factors associated with noncompliance, 
including factors such as disease severity and criticality, that put patients at different levels of 
health risks.  In decision making, beliefs determine intentions, which, in turn, determine actual 
behavior (Ajzen and Fishbein 1980).   
Smith et al. (1991) proposed that beliefs are derived from information that is processed 
using judgments and arguments. Although their work is based on the Toulmin Model of 
Argumentation (Toulmin 1958), it substantially varies in two areas: (1) they propose three 
modules that work interactively, not sequentially, and (2) they introduced screens of relevance 
and reliability through which information is judged. In the first module, data are retrieved 
internally from memory or externally through perception.  In the second module, these data are 
judged against the concepts of relevance and reliability to determine whether the data are worthy 
and applicable for argument construction.  Finally, in the third module, referred to as the 
reasoning or argument construction, these data are transformed into beliefs. 
The role of relevance and reliability judgments in belief formation has been addressed in 
several studies (Sewak 2002, West et al., 2004, Jalnawala and Wilkin 2004, Lobb 2007, King 
and Wilkin 2004).  Patients have used relevance judgments to assess the utility of the 
information and reliability judgments to assess the dependability of pharmacists (West et al. 
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2004).  In a consumer study of weight loss supplements, the relevance and reliability of the 
information were more predictive of beliefs than source credibility (King and Wilkin 2004).    
The impact of physician prescribing of off-label therapies on patients’ beliefs is 
unknown, including the effect on the physician-patient relationship and ability to exchange 
information which is important in the physician-patient relationship (Hall et al. 2002). 
 
Patient Trust in Physicians and Involvement in Medical Decision Making 
“Patient trust can be considered a collective good, similar to ‘social capital,’ that is 
necessary for an effective health care system” (Thom et al. 2004, p. 126).  The importance of 
trust in medical relationships has been acknowledged in the literature dating as far back as 1927, 
but the concept was not “systematically analyzed or measured” (Hall et al. 2002, p. 294) until the 
last 20 years.  The first scale was developed in 1990 (Anderson and Dedrick 1990).  Since then, 
several teams have been working in the area (Kao et al. 1998,  Hall et al. 2002, Thom et al. 1997, 
Thom et al. 1999, Safran et al. 1998).  Each team identified five overlapping 
domains/dimensions consisting of fidelity, competence, honesty, confidentiality, and global trust 
(Greenbridge 2011).  Despite efforts to identify and separate these unique dimensions, trust 
appears to be unidimensional; in fact, “the failure to differentiate between competence and other 
aspects of trust is especially notable” (Hall et al. 2002, p. 313). 
It is also important to note the distinction “between interpersonal trust, which 
characterizes a relationship between two individuals, such as a specific physician-patient 
relationship, and institutional or system trust, which characterizes attitudes toward collective or 
social organizations” (Hall et al. 2002, p. 297).  The large domain of trust seems to move beyond 
the individual physician.  The development of scales to test trust in different health care 
participants (e.g., payers or insurance companies) has been valuable, as it has been found that 
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HMO enrollees are less likely than those in non-HMOs to express trust in their physicians (Lake 
et al. 1999-2000).  Another study found that “disclosing the positive and negative features of 
incentives and increasing knowledge of these incentives does not, in the short term, reduce trust 
in physicians or insurers and may have a mild positive impact on trust in physicians, perhaps as a 
consequence of displaying candor and increasing understanding of positive features” (Hall et al. 
2002, p. 197).    
Trust in the medical profession has been found to be a significant predictor of self reports 
of many patient behaviors, including following physician treatment recommendations and 
willingness to rely on physicians’ judgment (Trachtenberg et al. 2005, Thom et al. 1999).  
Researchers concluded that a “trusting physician relationship may moderate the impact of cost 
pressures on patients’ medication adherence.  More generally, addressing noncost barriers to 
adherence may reduce rates of cost-related medication underuse” (Piette 2005, p. 1749).   
Appropriately ascribing the antecedents and determinants of trust will enable better 
interventions in this important and complex relationship.  The importance of this connection 
between trust and compliance grows as physicians move from a paternalistic role to more 
collaborative care involving the patient in health care decisions (Hammond and Lambert 1994) 
and as the influence of third parties grows. 
Patients’ preference on involvement in their medical decision making has been measured 
(Say et al. 2005).   Studies have found that these preferences are influenced by patients’ 
demographic variables, their experience of illness and medical care, their diagnosis and health 
status, the type of decision they need to make, the amount of knowledge they have acquired 
about their condition, their attitude toward involvement, and the interactions and relationships 
they experience with health professionals.  The connection with trust and involvement is also 
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complex and has been shown to be more closely associated with trust in the medical profession 
than trust in the individual physician (Trachtenberg et al. 2005).   
 
Disease Criticality 
Conditions affecting human health are not all created equal.  One can expect that chapped 
lips may result in different attitudes and behaviors than cancer.  Compliance has been shown to 
vary across different disease states and at times has been found to be more closely associated 
with the perception of risk than with the disease itself (Christensen 1978, Porter 1969).    The 
patient desire to be involved in medical decision making can evolve within a disease state as a 
patient progresses (Say et al. 2005) and has been shown to exist and vary in diseases of high 
criticality (Levinson et al. 2005), such as cancer (Bruera et al. 2001).  As with these other patient 
measures, the effect of off-label use may also vary across different disease states with different 
levels of immediate risk and magnitude of risk. 
 
Research Questions 
Given the widespread off-label use of pharmaceuticals (Radley et al. 2006, Peppercorn 
2008, Soares 2005, Pathak et al. 2010), one is led to question the effect of off-label use on patient 
decision making.  Nevertheless, the attitudes, beliefs, and behavioral intentions of patients 
regarding off-label use are largely unknown.  Only one study, conducted in German parents, 
exists.  This study shows the parents’ general ignorance of the occurrence of the behavior as well 
as a concern for their children (Lenk et al. 2009).  This research will address the following 
questions: 
 What are the roles of disease criticality, FDA approval status of the prescribed drug, 
and the “normal” level of off-label use in beliefs formed about the prescribed drug, 
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level of trust in physicians, level of involvement in medical decision making, and 
intentions of initial compliance? 
 What are the roles of relevance and reliability judgments of the physician-provided 
information and trust in physicians in the beliefs formed about a prescribed drug and 
the intentions of initial compliance? 
 How do the roles of these elements differ in a population of elderly patients when 
compared to younger patients? 
 
Study Significance 
There are no studies of patient perceptions of off-label use publicly available.  Although 
some studies have measured the existence of off-label use (Radley 2006, Soares 2005, Kauffman 
1996, Bazzano 2009, Peppercorn 2008, Pathak et al. 2010) and the need of market participants to 
address and regulate off-label use (Stafford 2008, Fairman 2010), virtually nothing is known 
about patient views of off-label prescribing.    
An estimated $258.3 billion is wasted each year in the health care system based on 
nonadherence with prescriptions (Express Scripts 2010).  Trust in physicians is associated with 
patient adherence (Hall et al. 2002), yet only one small study (Lenk et al. 2009) has addressed 
patient attitudes and behavioral intentions regarding this common phenomenon of off-label 
prescribing.   
Due to the importance to society of patient compliance, the frequency of off-label use 
within this market, and the value of trust in physician-patient relations, it is important to 
understand the potential effects of off-label use of pharmaceuticals in patient decision making. 
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CHAPTER II 
LITERATURE REVIEW 
 
Off-Label Prescribing 
Studies have found that 21% of commonly used drugs are used in indications for which 
the FDA has not specifically approved them (Radley 2006).  Up to 75% all oncology uses are not 
FDA approved (Soares 2005), and at least 80% of pediatric patients are prescribed products that 
lack an FDA approval for the use.  What remains unknown is how many of the 93% of 
consumers who are confident about the safety and effectiveness of drugs approved for use in the 
United States know this (Kauffman 1996, Bazzano 2009).  
Off-label use is so prevalent that physicians may not even know they are doing it.  Even 
when the set of drugs was limited to those that physicians prescribed, they only accurately 
identified the FDA status of commonly used drugs and the FDA approval status of common uses 
60% of the time: 
Physicians’ beliefs that individual drug-indication pairs were FDA-approved were 
strongly correlated with the level of evidence supporting the use in question.  However, a 
substantial minority of respondents believed that some drug-indication pairs without 
evidence supporting efficacy were actually FDA approved for the use in question.  For 
example, among the 42% of physicians who prescribed quetiapine (Seroquel
®
) for 
dementia with agitation during the previous 12 months, nearly one in five (19%) 
erroneously believed it was FDA-approved for this use, when in fact quetiapine has never 
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been FDA approved for this indication and at the time of our survey carried a black-box 
warning for “increased risk of death compared to placebo” in elderly patients with 
dementia.  (Chen et al. 2009) 
Off-label prescribing is especially common in the therapeutic areas of oncology, 
psychiatry, and pediatrics (Radley et al. 2006, Peppercorn 2008, Tarbarrok 2000, Bazzano 2009, 
Pathak et al. 2010).  Radley et al. used nationally representative data from the 2001 IMS Health 
National Disease and Therapeutic Index (NDTI) to classify the prescribing patterns by diagnosis 
for 160 commonly prescribed drugs.  Each reported drug-diagnosis combination was marked as 
(1) Food and Drug Administration approved, (2) off-label with strong scientific support, or (3) 
off-label with limited or no scientific support.  Multivariate analyses were unable to identify 
predictive characteristics of off-label drugs beyond belonging to the several drug classes that 
were largely known.  Of the estimated 150 million off-label mentions (21% of overall use), off-
label use was most common among cardiac drugs (46%, excluding antihyperlipidemic and 
antihypertensive agents) and anticonvulsants (46%).  The greatest proportions of off-label use 
among specific drugs were gabapentin (83%) and amitriptyline hydrochloride (81%).  An 
alarming finding was that 73% of off-label drug mentions had little or no scientific support.  
Previous studies were less robust and focused on specific drugs or therapeutic areas such 
as pediatrics, oncology, and psychology.  Bazzano et al. (2009) looked at outpatient pediatric 
visits and found that 62% included off-label prescribing.  Off-label prescribing was found to be 
common for many therapeutic areas:  96% of cardiovascular-renal, 86% of pain, 80% of 
gastrointestinal, and 67% of pulmonary and dermatologic medications.  Off-label prescribing 
was more likely in visits by children aged < 6 years, especially visits by children aged < 1 year.  
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Specialists were also more likely to use off-label prescribing (68% versus 59% for general 
pediatricians). 
In oncology, 75% of rituximab administrations were for off-label use at an academic 
center (Kocs et al. 2003).  This finding is consistent with Soares’ (2005) finding that 50% to 75% 
of all oncology therapies are off-label.  Over 80% of oncologists reported using investigational 
therapies for non-FDA approved uses (90% of academic oncologists and 75% of community 
oncologists) (Peppercorn 2008). 
Pathak and colleagues (2010) explored the prescribing of second generation 
antipsychotics in a state Medicaid pediatric population from 2001 to 2005 and the published 
support for the uses.  Use doubled over the time frame, yet 41.3% of new users lacked a 
diagnosis for which the treatment was supported by a published study.   
The off-label use of drugs is so common in cancer that the American Cancer Society 
(2011) Web site has a section entitled, “What questions should I ask my physician about off-
label drug use?” with the following guidance: 
Here are some questions you may want to ask your doctor.  Start by asking if all the 
drugs recommended for your cancer treatment are approved for the planned use.  If any 
of the drugs are not, you can ask: 
•  Is there evidence to support the off-label use of this drug to treat my type of cancer?  
•  Is this off-label drug likely to work better than an approved drug?  
•  What are the risks and benefits of off-label treatment with this drug?  
•  Will my health insurance cover off-label treatment with this drug?  
•  If my treatment involves a combination of drugs and one of the drugs is being used 
off label, will my health insurance cover it? 
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Cancer is relatively unique in that many oncologists may not be aware of the FDA- 
approved use of the drug, but they are likely aware of its compendia listing.  Compendia are 
often developed by expert panels that review the clinical data in support of products for 
particular uses.  When trying to get reimbursement from payers, 90% of oncology practice 
managers believe they have a better chance of getting paid for their treatment decision when they 
base their coverage argument on compendia (Cote 2008).  For oncologists, the utility of knowing 
the FDA-approved indication is minimized when the reality that compendia are richer resources 
of clinical data relative to FDA labels is combined with the fact that reimbursement is often tied 
to use in line with the compendia.  
In the United States, since 1962, a prescription drug must be proven safe and effective for 
the indications listed on its label before it is approved for marketing.  Former FDA Acting 
Director Steven Galson stated the following about an FDA approval and its associated safety and 
efficacy:   
What it means when a drug is approved is that the risks are outweighed by the benefits 
for the indication and under the conditions that are in the label. That just means if the 
drug is used in the right patients, in the right way, at the right dose, and there aren't drugs 
that are contraindicated taken with it, that the benefits outweigh the risks. There’s a lot 
that can go wrong that doesn’t fit under that definition. But the benefits outweigh the 
risks for the indication and under the conditions of use that we specify when we approve 
drugs, and the public should feel very comfortable with the review process.  (PBS 2011) 
Off-label prescribing is the use of a prescribed medication in a manner different from that 
approved by the FDA (Stafford 2008).  Physicians can legally rely on their professional 
judgment to use these FDA-approved products in different diseases, different aged patients, or 
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different doses that are not approved by the FDA.  In fact, legal scholars view guiding industry 
marketing as the primary purpose of FDA labeling.  This has led others to conclude that it is not 
the label but the strength of clinical evidence that physicians should be aware of and use to guide 
their prescribing (Beck and Azari 1998, Chen et al. 2009).  The FDA even condones off-label 
use when appropriate:   
Good medical practice and the best interests of the patient require that physicians use 
legally available drugs, biologics and devices according to their best knowledge and 
judgement.  If physicians use a product for an indication not in the approved labeling, 
they have the responsibility to be well informed about the product, to base its use on firm 
scientific rationale and on sound medical evidence, and to maintain records of the 
product’s use and effects.  (FDA 2011) 
Others have strongly supported its use, especially in rare diseases for which there are no drugs 
approved.  Given the lack of approved treatments for some diseases, in 1983 the Orphan Drug 
Act was passed to incentivize research and development that led to FDA approvals for these 
neglected diseases. 
Off-label use can encompass a broad range of prescribing with many different levels of 
risk.  Examples of off-label use are: 
 Different disease – an FDA-approved drug to treat blood pressure is used to treat 
migraine headaches 
 Different patients – an FDA-approved drug to treat depression is used in children less 
than 12 years of age even though it was not studied in this population 
 Different dose – an FDA-approved drug to treat a sinus infection is used at a higher 
dose than listed in the FDA-approved label. 
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Given the vast differences and risks under the off-label umbrella, some have even suggested a 
three-level evidentiary categorization system:  supported, suppositional, and investigational 
(Largent 2009). 
The US has seen the dangers of off-label use, such as the long-term use of the drug 
combination “Fen-Phen,” the components of which were approved as single agents for short-
term use.  Recently, the significant off-label use of Avastin
®
 in unapproved cancers at a cost of 
greater than $50,000 per year has not gone unnoticed by payers, yet its use was welcomed by 
some in the treatment of macular degeneration with a per treatment cost of < $150 compared to 
the leading alternative at $2,000 per treatment.   
Fairman (2010) discusses the controversy and contradiction based on the actions of the 
FDA, the Centers for Medicare & Medicaid Services (CMS), and the Department of Justice 
(DoJ).  Although it is legal in the US for physicians to use drugs off-label, it is not legal for drug 
companies to market FDA-approved drugs for off-label uses.  While the FDA is perceived as 
relaxing regulation, the DoJ is increasing its activities.  This legal action against the promotion of 
prescription drugs for off-label uses has resulted in billions of dollars in settlements and fines 
(examples:  Pfizer’s settlement for $2.3 billion in 2009, Eli Lilly’s charge for $1.4 billion in 
2009, Astra Zeneca’s payments of $520 million in 2010, and Allergan’s guilty plea resulting in 
$600 million in payments) (Fairman 2010, Law 2007).  Off-label marketing is very different 
from off-label use, and this study does not address the implications of off-label marketing. 
While the medical, regulatory, payer, pharmaceutical, and legal communities readily 
acknowledge that off-label prescribing is common, it appears that only one study (Lenk et al. 
2009) has measured patient perceptions and attitudes toward this prescribing behavior.  This 
study was based on 94 German parents and assessed their awareness and attitudes toward the use 
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of unlicensed products in their children.  Patient advocates for rare disease populations discuss 
the need for effective and safe therapies that better treat the target disease and therefore include 
the concept of off-label use in their communications (NORD 2011).  But even in these patients, 
who may be more aware of the concept of off-label use than the broader population, the effect on 
decision making has not been studied.  A void exists in the literature for studies assessing 
patients’ attitudes toward off-label use, perceived value of an FDA-approved indication, and 
decision making to comply with the physician prescribing of off-label drugs. 
 
Medication Compliance/Adherence 
Compliance is defined as the extent to which a patient takes the medication as prescribed 
by the health care provider.  Adherence is also used to describe this behavior, as it suggests the 
addition of patient agreement with the instructions and addresses the criticism that compliance 
suggests patient involvement is passive (Osterberg and Blaschke 2005, Bentley et al. 1999).   
There are numerous ways to deviate from perfect compliance with prescriber instructions.  
These actions can be either volitional or nonvolitional.  When the patient makes a conscious 
choice to be noncompliant with the instructions, it is a volitional action.  There are also various 
types of compliance (Table 2-1).     
With noncompliance costs estimated at > $250 billion annually (Express Scripts 2010), it 
is difficult not to feel compelled to address this problem despite its complexity.  It also must be 
addressed with an open mind and research, as intuition may lead many astray.  Kocurek (2009, p. 
80) discusses the common assumption that difficulty with taking medications occurs primarily in 
older adults:  “[H]owever, age itself has not been identified as a risk factor for medication 
nonadherence.”  Jo (2006) found that patients < 65 years of age and with fewer comorbidities 
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were more likely to be nonadherent.  Lobb (2007) identified younger patients as less likely to be 
compliant initially when out-of-pocket costs were high. 
 
Table 2-1: Definitions of Varying Types of Compliance 
Initial noncompliance The instance whereby patients fail to receive the medication 
prescribed for them.  It includes both unpresented and 
unclaimed prescriptions. 
Partial compliance The process of taking a prescribed and dispensed 
medication at a level less than was intended by the 
prescriber.  It includes premature discontinuation of 
therapy, missed doses, and late refills. 
Compliance The process of taking a prescribed and dispensed 
medication precisely as intended by the prescriber. 
Hypercompliance The situation in which a patient takes a prescribed and 
dispensed medication at a level over the prescriber’s 
intended dosing interval. 
Source:  Bentley et al. 1999 
 
 
After a review of the literature (1966 to 2002) on compliance among community-
dwelling older patients, Vik et al. (2004, p. 303) found that “polypharmacy and poor patient–
healthcare provider relationships (including the use of multiple providers) may be major 
determinants of nonadherence among older persons, with the impact of most sociodemographic 
factors being negligible.  There is little consensus regarding other determinants of 
nonadherence.”  The authors also report that as high as 11% of hospitalizations among older 
patients are attributable to nonadherence (Vik et al. 2004).  Improvements in patient-health care 
provider relationships may lead to a reduction in the burden of noncompliance. 
 
Patient Trust in Physician 
Thom et al. described trust: 
It’s been broken, misplaced, abused, shaken, and violated.  Occasionally it’s repaired and 
rebuilt.  Trust is a vulnerable and fragile commodity, vaunted in the marketplace, 
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acknowledged in every profession, yet perniciously difficult to quantify.  Marketers 
measure its value in brand loyalty, customer retention, product satisfaction, and sales.  In 
the health care marketplace, the absence or presence of trust in patient-provider relations 
can have life-changing consequences.  A person who trusts a provider is more likely to 
seek care, to comply with treatment recommendations, and to return for follow-up care 
than a person who has little trust in a specific provider or health care system.  Doesn’t 
that alone make it something worth measuring?  (Thom et al. 2004, p. 124) 
The same researchers (Thom et al. 2004, p. 126) described patient trust as “a collective good, 
similar to ‘social capital,’ that is necessary for an effective health care system.”   
In studies with patients, the following categories of physician behavior with a positive 
effect on trust generally were found:  competency, communication, caring, honesty, and 
partnering.  These are similar to interpersonal trust-promoting factors identified in psychology 
and sociology research:  (1) greater perceived mutual interests, (2) clear communication, (3) a 
history of fulfilled trust, (4) less perceived difference in power with the person being trusted, (5) 
acceptance of personal disclosures, and (6) an expectation of a longer-term relationship.  
“[T]hese associations suggest approaches that would be expected to increase patient trust, such 
as emphasizing mutual interests (the patient’s health); checking patients’ understanding of 
communication; taking opportunities to fulfill trust (phoning with test results); reducing power 
differences (sharing information); responding to patients’ self-disclosures in a supportive and 
nonjudgmental way; and promoting continuity of care” (Thom et al. 2004, p. 130). 
The first scale to measure this important driver of behavior was developed in 1990 
(Anderson and Dedrick 1990), and since then several teams have been working in the area (Kao 
et al. 1998,  Hall et al. 2002, Thom et al. 1997, Thom et al. 1999, Safran et al. 1998).  The 
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concept may readily appear multidimensional in a preliminary assessment, and the researchers 
each essentially identified five overlapping domains/dimensions consisting of fidelity, 
competence, honesty, confidentiality, and global trust (Greenbridge 2011).  However, efforts to 
identify and separate these unique dimensions have been unsuccessful.  Trust appears to be 
unidimensional.  In fact, “the failure to differentiate between competence and other aspects of 
trust is especially notable” (Hall et al. 2002, p. 313). 
Assessment of trust is further complicated by the realization that trust exists in many 
forms, given the complex relationships between the patient and the health care community, 
which is made up of individual physicians, the medical profession, other health care 
professionals and providers, institutions, payers, and more.  It is also important to note the 
distinction “between interpersonal trust, which characterizes a relationship between two 
individuals, such as a specific doctor-patient relationship, and institutional or system trust, which 
characterizes attitudes toward collective or social organizations” (Hall et al. 2002, p. 297).  The 
large domain of trust seems to move beyond the individual physician; thus, the development of 
scales to test trust in these different health care participants (e.g., payers or insurance companies) 
is also important.   
It is interesting to note that trust varies by religion (Benjamins 2006) and race (Keating 
2004).  Despite the complexity of trust and finding that trust formed with an individual physician 
is correlated with higher continuity (Mainous 2001), high levels of trust with specialists were 
found after only a single visit (Keating et al. 2004). 
Lake et al. (1999-2000) demonstrated that HMO enrollees had a lower likelihood of 
expressing trust in their physicians than non-HMO patients.  Given the complex structure of 
payers and the various financial relationships with physicians, one could be concerned about the 
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impact on trust in physicians.  To study this, members of two similar HMO plans were 
randomized to intervention and control groups.  The experimental arm was informed “how the 
HMO paid their primary care physician. Separate disclosures were developed for each plan, one 
describing primarily capitation payment, and the other (mixed-incentive plan) describing fee-for-
service payment with a bonus that rewards cost savings, satisfaction, and preventive services” 
(Hall et al. 2002, p. 197).  The disclosures, albeit they communicated more of the positive than 
the negative features of these incentives, had in informative aspect that may be similar to 
disclosing the existence of off-label prescribing to patients.  The researchers’ disclosure: 
[D]oubled the number of subjects with substantial knowledge of the physician incentives 
and halved the number with no knowledge.  Nevertheless, the disclosures had no negative 
effects on patient trust of either physicians or insurers.  The capitated plan disclosure had 
a small positive effect on trust of physicians.  Disclosing the positive and negative 
features of incentives and increasing knowledge of these incentives does not, in the short 
term, reduce trust in physicians or insurers and may have a mild positive impact on 
physician trust, perhaps as a consequence of displaying candor and increasing 
understanding of positive features.  (Hall et al. 2002, p. 197)    
In 2002, Thom et al. (p. 476) found that “[p]atients with a lower level of trust in their 
physician are more likely to report that requested or needed services are not provided” and then 
suggested that “[u]nderstanding this relationship may lead to better ways of responding to patient 
requests that preserve or enhance patient trust, leading to better outcomes.”  Additionally, trust in 
the medical profession has been found to be a significant predictor of many self-reported patient 
behaviors, including following physician treatment recommendations and willingness to rely on 
physician judgment (Trachtenberg et al. 2005, Thom et al. 1999).   
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Trust in the physician also affects initial compliance via willingness to pay.  Lower levels 
of trust in physicians were associated with an increased likelihood of forgoing medication with 
higher out-of-pocket costs.  Only in the context of low levels of trust in physicians did the 
researchers find an association with low income and cost-related adherence.  Researchers 
concluded that a “trusting physician relationship may moderate the impact of cost pressures on 
patients’ medication adherence.   More generally, addressing noncost barriers to adherence may 
reduce rates of cost-related medication underuse”  (Piette et al. 2005, p. 1749).  
Appropriately identifying the antecedents and determinants of trust will enable better 
interventions in this important and complex relationship.  The importance of understating the 
connection between trust and compliance grows as physicians move from a paternalistic role to 
more collaborative care involving the patient in health care decisions (Hammond and Lambert 
1994) and as the influence from third parties grows.  This change has even caused some to 
suggest that “too much trust” might harm patients in paternalistic relationships and as managed 
care grows (Gatter 2004, Buchanan 2000, Davies and Rundall 2000). 
 
Patient Involvement in Medical Decision Making 
In their review of the literature, Say and colleagues (2005, p. 102)  found that patients’ 
preferences of involvement in medical decision making are influenced by “demographic 
variables (with younger, better educated patients and women being quite consistently found to 
prefer a more active role in decision making), their experience of illness and medical care, their 
diagnosis and health status, the type of decision they need to make, the amount of knowledge 
they have acquired about their condition, their attitude towards involvement, and the interactions 
and relationships they experience with health professionals. Their preferences are likely to 
develop over time as they gain experience and may change at different stages of their illness.” 
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Interestingly, across multiple diseases, approximately two thirds of patients expressed a desire 
for shared decision making with the physician (Trachtenberg et al. 2005, Arora et al. 2000), even 
in cancer (Bruera et al. 2001).  Patients’ desire to be involved in decision making and the 
treatment process was inversely proportional to patients’ disease criticality in numerous diseases 
(Levinson et al. 2005, Arora et al. 2000). 
The connection with trust and involvement in medical decision making is not necessarily 
intuitive.  Trachtenberg and colleagues (2005, p. 345) describe the challenging relationship: 
Both patient trust and active patient involvement are desirable in their own right and 
because they are associated with improved health outcomes. Paradoxically, however, it 
might be thought that these 2 attributes are in sharp conflict.   
Patient trust might be more consistent with a deferential style of patient-physician 
interaction in which patients are passive, in contrast to assertive patient questioning or 
limitation of physician authority which might be indicative of patient distrust.  If so, then 
pursuing active patient involvement might lead to lower trust, or promoting trust might 
lead to more passive patients, either of which might compromise optimal treatment 
relationships and health outcomes.  At a minimum, it is a conceptual puzzle how these 2 
views of desirable attributes of medical relationships can coexist without each taking 
account of the other view. 
In their study of American adult patients (n = 553) who have seen a physician or other health 
professional at least twice in the past two years, they assessed preference of the patient’s role in 
medical decision making, trust in physician, trust in medical profession, and satisfaction with 
care.  They found that the most significant predictor of patients’ preferred role in medical 
decision making was trust in the medical profession (not the specific physician).  Views also 
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varied by sex, age, health, education, income, number of visits/years with physician, past dispute 
with a physician, and satisfaction with care.  Views varied slightly by trust in the specific 
physician. 
 
Patient Decision Making 
It is probably difficult to overestimate the complexity of patient decision making.  
Fincham and Wertheimer (1985) identified more than 250 social, economic, medical, and 
behavioral factors associated with noncompliance.   
In decision making, beliefs determine intentions which determine actual behavior (Ajzen 
and Fishbein 1980).  The theory of planned behavior has been studied extensively in many 
settings; however, it failed to explain how beliefs were formed.  
Beliefs are expectations about reality that are formed by practical reasoning or arguments 
(Smith et al. 1991).  Smith, Benson, and Curley’s model of belief formation was influenced by 
the work in argument theory of Toulmin (1958).  In Toulmin’s model, data are assessed to form 
claims through a process of judgments and reasoning (Figure 2-1). 
 
Figure 2-1:  Toulmin’s Argument Model 
Source: Toulmin 1958 
 
An argument or claim is determined by acquisition of the data and the warrant or judgment made 
about the data.  The warrant provides structure to an argument and justifies the leap from data to 
Data
Warrant
Claim
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claims (Boller et al. 1993).  Warrants are the key elements that reflect the assumptions of an 
argument (Smith et al. 1991) and drive the categorization of arguments into three main types: 
1. Substantive arguments − The warrant in substantive arguments is an assumption 
concerning the relationship existing among phenomena in the external world.  This 
includes causal arguments (e.g., my positive experience with a drug shows the drug is 
of value to me). 
2. Authoritative arguments − Unlike substantive arguments, authoritative arguments 
consist of factual reports or statements of opinion. The warrant in an authoritative 
argument affirms the reliability and credibility of the source (e.g., the drug is of value 
to me because the knowledgeable physician said it would be beneficial to me).   
3.  Motivational arguments − In motivational arguments, the data consist of one or more 
statements that may have been established as claims in a previous argument or series 
of arguments.  The warrant indicates a motive for accepting the claim by linking it 
with inner drive, desire, value, emotion, aspiration, or a combination of such forces. 
Although the work of Smith, Benson, and Curley is based on this Theory of Argument 
(Toulmin 1958), it substantially varies in two areas:  (1) they propose three modules (Figure 2-2) 
that work interactively, not sequentially, and (2) they introduced screens of relevance and 
reliability (Figure 2-3) through which information is judged.  In the first module, data are 
retrieved internally from memory or externally through perception.  In the second module, these 
data are judged against the concepts of relevance and reliability to determine whether the data 
are worthy and applicable for argument construction.  Finally, in the third module, referred to as 
the reasoning or argument construction, these data are transformed into beliefs. 
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Figure 2-2:  Smith, Benson, and Curley Model of Belief Processing 
 
Source: Smith et al. 1991 
 
 
Experiences have been shown to play a mixed role in the arguments that are used to form 
beliefs.  West et al. (2003, p. 1140) examined the role of experience in the formation of patients’ 
beliefs about pharmacist trustworthiness and found that as patients “gain experience with a 
situation, they are more likely to use their experience to form causal arguments and less likely to 
rely solely on external sources [to form beliefs].”  However, a study by Jalnawala and Wilkin 
(2004) found that authoritative arguments induced more favorable beliefs about the advertised 
medication than causal arguments.   
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Relevance and Reliability Measures 
A depiction of this portion of the reasoning module (Jalnawala 2005) is presented in 
Figure 2-3. 
 
Figure 2-3:  Information to Belief, the Role of Relevance and Reliability 
  
 
 
 
 
 
 
 
 
Source:  Jalnawala 2005 
 
 
Here the data that are considered to be relevant and reliable are admitted through the cognitive 
screen, while the data that are considered irrelevant and unreliable are discounted, thereby 
exerting minimal influence on beliefs. 
The role of relevance and reliability judgments in belief formation has been addressed in 
several studies (Sewak 2002, West et al. 2004, Jalnawala and Wilkin 2004, Lobb 2007, King and 
Wilkin 2004).  Patients have used relevance judgments to assess the utility of the information 
and reliability judgments to assess the dependability of pharmacists (West et al. 2004).  In a 
consumer study of weight loss supplements, the relevance and reliability of the information were 
more predictive of beliefs than source credibility (King and Wilkin 2004).  The judgments of 
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relevance and reliability seem to be more powerful regulators of information in the process of 
belief formation than the judgment of a source’s credibility (Jalnawala 2005). 
 
Conceptual Framework  
 
 The model shown in Figure 2-4 was developed to show the proposed relationships among 
the studied concepts.   
 
Figure 2-4:  Conceptual Framework 
 
 
 
 
Research Questions 
The literature review revealed that:   
(a) Widespread off-label use of pharmaceuticals exists and level varies by disease state.   
(b) Little is known of patients’ attitudes and perceptions of off-label use. 
(c) Compliance can be positively correlated with disease severity/criticality. 
(d) Trust in physicians has increased compliance with treatments. 
(e) Patient involvement in medical decision making has been shown to decrease with 
disease severity/criticality.  
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(f) Physician-provided communications have been demonstrated to reduce the level of 
volitional noncompliance. 
(g) The patient-judged relevance and reliability of the information provided by the health 
care provider can determine the beliefs about the drug and intentions to be compliant. 
These givens led to several research questions: 
 What are the roles of disease criticality, FDA approval status of the prescribed drug, and 
the “normal” level of off-label use in beliefs formed about the prescribed drug, level of 
trust in physicians, level of involvement in medical decision making, and intentions of 
initial compliance? 
 What are the roles of relevance and reliability judgments of the physician-provided 
information in the beliefs formed about a prescribed drug and the intentions of initial 
compliance? 
 How do the roles of these elements differ in a population of elderly patients when 
compared to younger patients? 
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CHAPTER III 
RESEARCH DESIGN AND METHODS 
 
This chapter discusses the study design, sampling, operationalization of the variables, 
questionnaire design, data collection, and data analysis plan.  The method was approved by the 
University of Mississippi Institutional Review Board. 
 
Study Design 
 The goal of this study was to examine the effects of off-label use on patients’ trust of the 
physician, involvement in medical decision making, initial compliance, and beliefs toward the 
drug.  A cross-sectional design, the most commonly used survey design (Singleton and Straits 
1999), was used in this study.  Data were collected using a self-administered online questionnaire 
which asked respondents about their opinions on various factors under different off-label 
scenarios (presented in the Appendix) based on a 2 × 2 × 2 design.   Each respondent was 
exposed to one of eight scenarios with the following manipulations:  (1) disease (varying by 
criticality), (2) the normal level of off-label use for this disease, and (3) the FDA approval status 
of the prescription for this disease. 
 
Sampling    
Data to test the propositions and hypotheses were collected from a stratified random 
sample of consumers from an on-line panel.  Stratifying by variables correlated with the 
dependent variables increases the precision of estimates because it systematically introduces 
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relevant sources of variability in the population into the sample.  The strata were based on age,  
≥ 65 years of age and < 65 years of age.  Those  ≥ 65 years of age qualify for prescription drug 
coverage by Medicare Part D.  Previous research has shown differences in initial compliance by 
age (Lobb 2007).  Similar to previous research (Lobb 2007), a quota sampling technique was 
used to achieve 800 respondents, enabling cell sizes of 50 in the 2 × 2 × 2 design for the ≥ 65 
years of age and < 65 years of age arms of the study.  The sample was limited to respondents 
who were current users of prescription drugs and/or who had purchased at least 1 prescription 
drug in the previous 12 months. 
A common criticism of online sample frames is that the sub-population may not reflect 
the broader population, but this is changing as more US citizens are online (Sheehan 2006).  The 
consumer panels of Research Now, a professional market research company, served as the 
sample frame, and the demographics of the sample frame can be compared to the US population.    
Nonresponse bias was assessed in two manners.  First, demographic data were requested 
from those who did not meet inclusion criteria.  Second, the demographics of the sample were 
tested against the demographics of the full panel, or sample frame.   
 
Operationalization of Dependent Variables  
Trust in the Physician 
Although scales date back to 1990 (Anderson et al.), the Wake Forest Physician Trust 
Scale developed by Hall et al. in 2002 is likely the most accepted scale (Thom et al. 2004).  A 
short version of this five-item scale has been validated (Dugan et al. 2004) and even used in a 
study associated with patient involvement in medical decision making (Trachtenberg et al. 2005).  
The scale is designed for measuring trust in an individual physician, not trust in the medical 
profession.  This matches the scenario in which the respondent will be asked to assess trust in the 
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specialty physician prescribing the on-label or off-label drugs.  Research has found that even 
high levels of trust can form in a specialist physician in an initial visit (Keating et al. 2004).  
Below are the five items that have been modified to assess trust in the scenario’s prescribing 
physician: 
After reading each statement, rate how much you agree or disagree with each statement: 
Strongly Agree        Agree         Neutral       Disagree          Strongly Disagree 
                                                                                            
 
1. Sometimes this [oncologist/allergist] cares more about what is convenient for 
(him/her) than about your medical needs. 
2. This [oncologist/allergist] is extremely thorough and careful. 
3. You completely trust the [oncologist/allergist]’s decisions about which medical 
treatments are best for you. 
4. This [oncologist/allergist] is totally honest in telling you about all of the different 
treatment options available for your condition. 
5. All in all, you have complete trust in this [oncologist/allergist]. 
 
 
Relevance and Reliability of Information 
 Supported by the several studies (Sewak 2000, West et al. 20004, Lobb 2007, Jalnawala 
2005) and based on the model proposed by Smith et al. (2005), the relevance and reliability of 
information presented in the scenarios acts as a filter that determines which information becomes 
evidence for the argument.  In previous studies, an eight-item, nine-point semantic differential 
scale has been used for relevance and reliability assessments (five items for relevance and three 
for reliability).  Given the mixed results of previous studies, an exploratory factor analysis was 
conducted to assess the dimensionality of the scale to determine whether the two measures were 
the same or separate constructs.  The reliability of the scale was evaluated using Cronbach’s 
alpha. 
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In this scenario, I believe the information provided by the [oncologist/allergist] is: 
Undependable 1 2 3 4 5 6 7 8 9 Dependable 
Not helpful 1 2 3 4 5 6 7 8 9 Helpful 
Unimportant 1 2 3 4 5 6 7 8 9 Important 
Consistent 1 2 3 4 5 6 7 8 9 Inconsistent 
Meaningful 1 2 3 4 5 6 7 8 9 Meaningless 
Irrelevant 1 2 3 4 5 6 7 8 9 Relevant 
Unreliable 1 2 3 4 5 6 7 8 9 Reliable 
Useless 1 2 3 4 5 6 7 8 9 Useful 
 
 
Patient Involvement in Medical Decision Making 
The desire of patients to be involved in the decision making of their medical care varies 
significantly (Arora et al. 2000, Levinson et al. 2005).  Approximately two thirds of patients 
express a desire for shared decision making with the physician (Trachtenberg et al. 2005, Arora 
et al. 2000), even in cancer (Bruera et al. 2001).   The scale below was adapted from the one used 
by Trachtenberg et al. (2005) to assess the correlation between patients’ trust and their attitudes 
toward seeking care, participating in medical decision making, and adhering to treatment 
recommendations: 
After reading each statement, rate how much you agree or disagree with each statement 
regarding the scenario you just read. 
 
Strongly Agree        Agree         Neutral       Disagree     Strongly Disagree 
                                                                                    
 
1. I will always follow this [oncologist/allergist]’s recommendations about treatment.  
2. It is better to rely on the expert judgment of this [oncologist/allergist] than to rely on 
common sense in taking care of my own body. 
3. It is better to seek professional help than to try to treat myself.  
4. Concerning my medical care, I should take complete control. 
5. Concerning my medical care, the [oncologist/allergist] should take complete control. 
6. In my future visits with the [oncologist/allergist], I believe I will make all of the final 
decisions. 
7. In my future visits with [oncologist/allergist], I believe the [oncologist/allergist] 
should take the initiative and decide what is best for me. 
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Belief Measures about the Drug 
Previous research has shown that patients will develop different beliefs about the drugs 
based on different stimuli (Sewak 2000, West et al. 20004, Lobb 2007).  These beliefs about a 
prescription drug were directly measured with eight semantic differential questions Sewak 
(2000) adapted from the work of Petty and Cacioppo: 
 
I believe that the drug I have been prescribed is: 
Bad 1 2 3 4 5 6 7 Good 
Unfavorable 1 2 3 4 5 6 7 Favorable 
Harmful  1 2 3 4 5 6 7 Beneficial 
Useless 1 2 3 4 5 6 7 Useful 
Ineffective 1 2 3 4 5 6 7 Effective 
Unnecessary 1 2 3 4 5 6 7 Necessary 
Dangerous 1 2 3 4 5 6 7 Safe 
Not helpful 1 2 3 4 5 6 7 Helpful 
 
 
The Cronbach’s alpha for the belief items in the Sewak study was 0.84.  Lobb added 
three items to measure beliefs about the out-of-pocket prescription costs.  The Cronbach’s alpha 
for the three items was 0.69.  The items were added to this study as well to assess beliefs about 
the drug. 
 
Not valuable 1 2 3 4 5 6 7 Valuable 
Expensive 1 2 3 4 5 6 7      Cheap 
Not worth the cost 1 2 3 4 5 6 7 Worth the cost 
 
The reliability of these scales was evaluated using Cronbach’s alpha, and the additional items 
were evaluated before adding them to the drug belief scale.   
 
Initial Compliance Intention 
In previous research, the four-item, nine-point semantic differential scale below has been 
used to measure intention of patients to request or fill a prescription medication after seeing a 
 33 
stimulus (West et al., 2004, Jalnawala and Wilkin 2004, Lobb 2007).  The scale has been found 
to be a sufficiently reliable measure of the construct of behavioral intention (Cronbach’s alpha = 
0.98 in Lobb 2007). The same scale was adapted in the context of physicians’ “likelihood to 
prescribe” a medication and had a Cronbach’s alpha = 0.94 (Jalnawala 2005).  Compliance after 
the initial fill was not measured, as that may be driven more by experience with the drug than the 
information provided by the physician.  West et al. (2003, p. 1140) found that the “role of 
external sources in influencing the formation of beliefs about trustworthiness of a pharmacist 
may be limited as a patient gains pharmacy experience, as experience is based on causal 
associations.”   
 
Based on the information available in this scenario, how likely are you to purchase this 
prescribed drug? 
 
No chance 1 2 3 4 5 6 7 8 9 Sure to purchase 
Likely 1 2 3 4 5 6 7 8 9 Unlikely 
Not possible 1 2 3 4 5 6 7 8 9 Very possible 
Certain not to purchase 1 2 3 4 5 6 7 8 9 Certain to purchase 
 
 
Operationalization of Independent Variables  
 The three variables that set up the 2 × 2 × 2 design and the resulting 8 scenarios to be 
seen by the respondent were (1) disease state, (2) a disease state specific measure of “normal” 
off-label use, and (3) the FDA approval status of the drug for the specific disease. 
 
Disease Criticality 
 The amount of off-label use varies by disease state (Radley 2006) and can skew high for 
oncology and allergies (Radley 2006, Peppercorn 2008, Poole 2004, Soares 2005).  Depending 
on the disease, prescribers and patients have historically been willing to accept different risks 
with regard to drug use (e.g., a drug that significantly reduces immune levels may be used to 
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treat cancer but would not be used to treat a common ear infection) (Harrison et al. 2005, Denig 
et al. 1988).   Patient compliance has also been found to vary by disease state and perceptions of 
the associated risks (Christensen 1978, Porter 1969).  Cancer and allergies were selected for this 
study to represent actual disease areas with high levels of off-label use and to represent 
differences between critical, life-threatening diseases and common, non-life-threatening 
ailments.  The variable was coded so that a value of “0” was for allergies and “1” was for cancer.  
 
“Normal” Off-Label Use 
 To convey to the patient that the physician is or is not acting in accordance with medical 
norms, two levels of “normal” off-label use were selected.  To convey a high or common use of 
off-label prescribing in the specific disease, the patient was told that a “national survey shows 
75% of the patients in the US with this type of [cancer/allergy] receive drugs that are approved 
by the FDA to treat this type of [cancer/allergies].  The other 25% receive drugs that are not 
approved by the FDA to treat this type of [cancer/allergies].”  To convey a minority use of off-
label prescribing, the percentages were reversed.  The 75% metric is representative of the higher 
levels found in studied diseases and has been associated with oncology and psychiatry (Radley et 
al. 2006 and Soares 2005).  The variable was coded as having a value of “0” for 25% use of off-
label drugs and “1” for 75% use of off-label drugs.  
 
FDA Approval Status of the Drug for the Specific Disease  
 Consumers have shown a high level of confidence in the safety and effectiveness of drugs 
approved for use in the United States (PWC 2010).  However, no studies have assessed patients’ 
opinions or assumptions of FDA approval for their uses of the product.  Patients may assume 
their FDA-approved drugs are approved for their specific use.  The respondents in this study 
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were explicitly told that the prescription they received was written for a drug that a) was 
approved or b) was not approved by the FDA for this type of [cancer/allergies].  The variable 
was coded as having a value of “0” for FDA approval and “1” for non-FDA approval.  
 
Other Independent Variables  
Trust in the FDA 
 Previous research has shown that despite 93% of patients being confident about the safety 
and effectiveness of drugs approved for use in the United States, roughly one third to over one 
half feel negatively about how the FDA is doing its perceived job (Pricewaterhouse Coopers 
2010, Harris Interactive 2008).  These studies measured expectations and perceptions but did not 
appear to inform the respondents of the stated responsibilities of the FDA.  In informing all 
respondents of the responsibilities of the FDA with regard to drugs especially, the following 
information from the FDA (2011) Web site was provided: 
FDA is responsible for protecting the public health by assuring the safety, 
efficacy and security of human and veterinary drugs, biological products, medical 
devices, our nation’s food supply, cosmetics, and products that emit radiation. 
FDA is also responsible for advancing the public health by helping to speed 
innovations that make medicines more effective, safer, and more affordable and by 
helping the public get the accurate, science-based information they need to use medicines 
and foods to maintain and improve their health. 
 To measure trust in the FDA, the five-item scale that was used to measure trust in 
physicians by Dugan et al. (2004) was adapted.  A five-point Likert-like scale with the items 
shown below was used to measure trust in the FDA.  The sixth item was added to assess trust in 
the FDA specifically with regard to regulating prescription drugs.  
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Strongly Agree        Agree         Neutral       Disagree          Strongly Disagree 
                                                                                            
 
1. The FDA is extremely thorough and careful.  
2. I completely trust the FDA’s decisions about which medical treatments are safe and 
effective. 
3. The FDA would never mislead me about anything. 
4. Sometimes the FDA cares more about what is convenient for them than about the 
patients’ medical needs. 
5. All in all, I trust the FDA completely. 
6. All in all, I trust completely in the FDA’s ability to regulate prescription drugs. 
 
 
Opinions of Off-Label Use 
At this time, no studies have assessed patients’ perspectives of off-label prescribing.   The 
following description of off-label use was given: 
This study will involve off-label prescribing — the prescription of a medication in 
a manner different from that approved by the FDA.  In the United States, since 1962, in 
order for prescription drugs to be allowed in the market, they must have been proven safe 
and effective when treating the disease states that are listed in each drug’s label, or on 
label.  One previous FDA leader simplified the meaning of an FDA approval by saying 
something similar to this:   FDA approval means if the drug is used in the right patients, 
in the right way, at the right dose, then the benefits outweigh the risks. 
  However, once approved by the FDA and marketed in the United States, doctors 
can legally rely on their professional judgment to use these FDA approved products to 
treat different diseases, even if those uses are not specifically approved by the FDA.  This 
is called off-label use. 
To explore the beliefs of patients about this phenomenon, the following items were 
created and agreement was tested: 
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Strongly Agree        Agree          Neutral        Disagree          Strongly Disagree 
                                                                                            
 
1. I believe the majority of prescriptions in the US are prescribed on label to treat 
diseases for which they are FDA approved. 
2. I believe it is safe to use FDA approved drugs off label to treat other diseases than for 
what they were originally approved. 
3. I believe most physicians know when a drug is FDA approved or not approved to 
treat the disease in which they are prescribing it. 
4. I believe insurance companies check to make sure the drug prescribed by the 
physician is being used on label to treat a disease for which it has been FDA 
approved. 
5. I believe pharmacists check to make sure the drug prescribed by the physician is 
being used on label to treat a disease for which it has been FDA approved. 
6. I believe all of the drugs I take are on label - FDA approved for the disease in which I 
use the drugs. 
7. I believe drugs that are used on label - FDA approved for a disease - are always more 
effective than drugs that are used off label – not FDA approved for that disease. 
8. I believe drugs that are on label - FDA approved for a disease - are always safer than 
drugs that are off label - not FDA approved for that disease. 
9. I only want to be prescribed drugs that are on label - FDA approved to treat the 
specific disease I have.  
10. I believe doctors who prescribe drugs off label for diseases for which the drugs are 
not FDA approved are superior doctors. 
11. I believe doctors who prescribe drugs off label - for diseases for which the drugs are 
not FDA approved - only do so because it is the best option for their patient. 
12. I believe doctors only prescribe drugs off label - for diseases for which the drugs are 
not FDA approved - for very rare diseases, not for more common ones. 
13. For children, I believe doctors only prescribe drugs on label - for diseases for which 
the drugs are FDA approved. 
 
 
Demographic Variables 
 
To reduce respondent fatigue, demographic assessments were placed at the end of the 
questionnaire.  The demographic variables included age, gender, ethnicity, education, marital 
status, annual household income, religion, and employment status.  Lobb (2007) found that 
patients > 65 years of age were higher in initial compliance intent than younger patients. 
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Social Desirability Assessment 
 
Previous studies have shown positive correlation and no correlation between social 
desirability and compliance measures (Wang et al. 2002, Burge et al. 2005).  Of the several 
techniques used to control social desirability response (Paulhus 1991), the demand reduction and 
covariate techniques were selected for use.  Demand reduction technique is based on assuring 
respondents of their anonymity.  The covariate technique involved administering the short 
version of the Marlowe-Crowne Social Desirability Scale developed by Strahan and Gerbasi 
(1972) along with the content measures.  This short form, based on a scale using 1 = Strongly 
disagree to 7 = Strongly agree, has been found to be superior to other forms (Fischer and Fick, 
1993):  
1. I always try to practice what I preach. 
2. There have been occasions when I took advantage of someone. 
3. I have never been irked when people expressed ideas very different from my own. 
4. At times I have really insisted on having things my own way. 
5. I am always willing to admit it when I make a mistake. 
6. I like to gossip at times. 
7. I never resent being asked to return a favor. 
8. I sometimes try to get even rather than forgive and forget. 
9. I have never deliberately said something that hurt someone’s feelings. 
10. There have been occasions when I felt like smashing things. 
Correlations were run between the social desirability measure and all other measures.  
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Questionnaire Design and Pretesting 
 The self-administered online questionnaire followed the order described here. After 
reviewing and responding to information about the role of the FDA and an explanation of off-
label use, the respondents were given one of eight scenarios.  They were asked to imagine 
themselves in a situation in which they were sick.  To remove bias associated with their current 
trust in the patients’ primary care physicians, the scenarios had them first seeking care, as one 
commonly would, from their primary care physician who then sends them to the appropriate 
specialist based on the illness.  To impose risk with the drug that may not exist with a short 
course of therapy, the patients were told they would have to take it daily for six months.  After 
reviewing the scenario, the respondents were given the assessments for (1) trust in physician,   
(2) the relevance and reliability of the information provided by the physician, and (3) patient 
involvement in medical decision making.  Next, the respondents were told that they take the 
prescription of the specialist to the pharmacy to be filled and the copayment is similar to other 
prescriptions they have received in the past.  Beliefs about the prescribed drug and initial 
compliance were then measured.  Social desirability and demographics were assessed, and the 
survey ended with a respondent debrief.  A copy of the questionnaire is shown in the Appendix. 
 To assess for face and content validity, the questionnaire was pretested with a 
convenience sample comprised of Medicare Part D patients (n=3) and commercial patients < 65 
years of age (n=4).  Following testing, these respondents were debriefed.  The same screening 
criteria were used as in the main study.  Manipulation checks were based on differences derived 
from the manipulations with the disease state and levels of off-label use of drugs for that disease.  
The manipulations were determined to have the desired perception. 
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Data Collection and Cleaning 
 After approval was obtained from the University of Mississippi’s Institutional Review 
Board, the survey was pre-tested as described.  For the main data collection a professional 
market research company, Research Now, was contracted to administer the survey to its online 
consumer panel that met the screening criteria.   
 Using the on-line method of collection, the responses were entered directly into an 
electronic database.  Although the likelihood of data entry errors was low using this method, the 
data were still checked for outliers and errors. 
 Microsoft
®
 Excel (version 2007) and SPSS
®
 (version 19) were used to manage and 
analyze the data. 
 
Analysis Plan 
 An analysis plan was developed to assess the research propositions and hypotheses.  
Given the general lack of studies assessing patients’ attitudes and perceptions of off-label use, 
propositions were used in lieu of hypotheses.  When theoretical support existed, the hypotheses 
were tested.       
 All tests of significance were conducted at the 0.05 level of significance.  Demographic 
variables and other descriptive statistics were used to characterize the respondents.  For measures 
of beliefs about the medication, likelihood to purchase the medication, relevance and reliability 
of the information presented by the specialists, and patient involvement in medical decision 
making, the scale scores were summed.  Cronbach’s alpha was used to measure reliability of the 
scales.  Values greater than 0.7 were considered reliable (Hair et al. 1998).  Summated scales 
have been found to reduce measurement error by using multiple indicators to reduce the reliance 
 41 
on a single response and maintain parsimony by representing multiple aspects of a concept in a 
single measure (Hair et al. 1998).    
 After assessing the scale’s internal consistency using Cronbach’s alpha, each scale’s 
items were examined using exploratory factor analysis (EFA).  The exploratory factor analysis 
was used to assess the factor structure of the data (Hair et al. 1998).     
 
Research Question 1.  What are the roles of disease criticality, FDA approval status of the 
prescribed drug, and the “normal” level of off-label use in beliefs formed about the prescribed 
drug, level of trust in physician, level of involvement in medical decision making, and intentions 
of initial compliance? 
 
 The analysis of the research propositions tested each of the directional propositions in its 
null form.  For the following propositions, t tests were used to determine whether the two group 
means were statistically different from each other (Hair et al. 1998).   
P1 The prescribing of an FDA-approved drug leads to a greater likelihood of patient initial 
compliance intention with a prescription than prescribing off-label. 
P2 The prescribing of an off-label FDA-approved drug when the norm is to use FDA-
approved products leads to a lower likelihood of patient initial compliance with a 
prescription than prescribing an FDA-approved drug. 
P3 The prescribing of an off-label FDA-approved drug in a more critical disease leads to a 
greater likelihood of patient initial compliance with a prescription than in a less critical 
disease. 
P4 The prescribing of an FDA-approved drug leads to a greater trust in the physician than 
prescribing off-label. 
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P5 The prescribing of an off-label FDA-approved drug when the norm is to use FDA-
approved products leads to lower trust in the physician than prescribing an FDA-
approved drug. 
P6 The prescribing of an off-label FDA-approved drug in a less critical disease leads to a 
lower trust in the physician than in a more critical disease. 
P7 There is no difference in the likelihood of patient involvement in medical decision 
making when an FDA-approved drug is prescribed than when an off-label drug is 
prescribed. 
P8 There is no difference in the likelihood of patient involvement in medical decision 
making when being prescribed an FDA-approved drug when the norm is to use FDA-
approved products than prescribing an off-label drug.  
P9 There is no difference in the likelihood of patient involvement in medical decision 
making when being prescribed an off-label drug in a critical disease than in a less critical 
disease.  
P10 The prescribing of an FDA-approved drug leads to stronger positive beliefs about the 
drug than prescribing off-label. 
P11 The prescribing of an off-label FDA-approved drug when the norm is to use FDA-
approved products leads to weaker positive beliefs about the drug than prescribing an 
FDA-approved drug. 
P12 The prescribing of an off-label FDA-approved drug in a less critical disease leads to 
weaker positive beliefs about the drug than in a more critical disease. 
 Exploratory multiple regressions were used to measure the effects of diseases state 
(DISCRIT), normal level of FDA-approved product use (OFFUSELVL), and FDA approval 
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status (FDASTAT) on beliefs of the drug initial compliance intent, trust in the physician, and 
involvement in medical decision making:   
 
Beliefs of the drug = DISCRIT + OFFUSELVL + FDASTAT + DISCRIT*OFFUSELVL + 
DISCRIT*FDASTAT + OFFUSELVL*FDASTAT + DISCRIT*OFFUSELVL*FDASTAT 
 
Initial compliance = DISCRIT + OFFUSELVL + FDASTAT + DISCRIT*OFFUSELVL + 
DISCRIT*FDASTAT + OFFUSELVL*FDASTAT + DISCRIT*OFFUSELVL*FDASTAT 
 
Trust in the physician = DISCRIT + OFFUSELVL + FDASTAT + DISCRIT*OFFUSELVL + 
DISCRIT*FDASTAT + OFFUSELVL*FDASTAT + DISCRIT*OFFUSELVL*FDASTAT 
 
Involvement in medical decision making = DISCRIT + OFFUSELVL + FDASTAT + 
DISCRIT*OFFUSELVL +  DISCRIT*FDASTAT + OFFUSELVL*FDASTAT + 
DISCRIT*OFFUSELVL*FDASTAT 
 
Multiple regression allows for the simultaneous assessment of relationships between each 
independent variable and the dependent measure (Hair et al. 1998).  Multiple regression was 
selected for its ability to model interactions, including two-way and three-way interactions, and 
identify issues such as multicollinearity.  The variables including interactions were all entered in 
one step, and the interactions were removed as they were found not to be significant.  The data 
were assessed to ensure that they met the assumptions of regression, namely linearity of the 
phenomenon, constant variance of the error terms, independence of the error terms, and 
normality of the error terms (Hair et al. 1998). 
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Research Question 2.  What are the roles of relevance and reliability judgments of the physician-
provided information in the beliefs formed about a prescribed drug and the intentions of initial 
compliance? 
 
H1 The higher the judged relevance and reliability of the physician-provided information are, 
the stronger the positive beliefs formed about the prescription product will be. 
H2 The higher the judged relevance and reliability of the physician-provided information are, 
the greater the initial compliance intention will be. 
 
For hypotheses 1 and 2, a bivariate correlational analysis was run.  Pearson’s correlation 
coefficient was used as the measure of association between the physician-provided information 
relevance and reliability and (1) beliefs about the medication and (2) initial compliance intention.   
 
Research Question 3.  How do the roles of these elements differ in a population of elderly 
patients when compared to younger patients? 
 
These propositions for the age-related differences were tested using a series of 
independent t tests:  
P13 Elderly (≥ 65 years old) patients differ from younger patients in responses to behavior of 
off-label use, trust in physician, and initial compliance intentions. 
P13oA In the same off-label scenarios, elderly patients do not differ from younger patients in the 
strength of the beliefs formed about the prescription. 
P13oB In the same off-label scenarios, elderly patients do not differ from younger patients in 
their initial compliance intentions measured by a multi-item scale. 
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P13oC In the same off-label scenarios, elderly patients do not differ from younger patients in 
their judgments of relevance and reliability of physician-provided information. 
P13oD In the same off-label scenarios, elderly patients do not differ from younger patients in 
their trust in physicians. 
P13oE In the same off-label scenarios, elderly patients do not differ from younger patients in 
their involvement in medical decision making. 
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CHAPTER IV 
RESULTS 
 
 Despite the use of off-label prescribing being common, no studies have investigated the 
effect of non-FDA approved uses of pharmaceuticals on patient decision making.  This study 
was conducted with Research Now’s online panel with the goal of obtaining 800 responses 
between 2 age groups:  (1) elderly (≥ 65) and (2) nonelderly (< 65).  The results of this study 
designed to enhance understanding of the effects of off-label prescribing are presented here.  
 
Data Cleaning and Manipulation  
 
Data were checked for outliers and errors.  Of the 838 respondents, 8 individuals initially 
responded to the age-related questions used to select scenarios in a manner that later did not 
appropriately match their stated year of birth.  These were eliminated from the sample. 
All fields were required for completion of the survey; thus, no missing data were handled.  
Reverse-coded items were recoded for appropriate scale assessments and summations. 
 
Demographics 
 The sample frame was an online panel.  The average age for respondents was 59.0 years, 
with 60% being female.  The panel was educated, with almost 70% completing at least a 2-year 
degree program, and 87.6%  reported being white/Caucasian.  Household income was reported as 
more than $45,000 for 76.4% of respondents.  The demographic data are shown in the aggregate 
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and for the elderly and nonelderly groups in Tables 4-1 and 4-2.  Group means are reported in 
Table 4-3.  
 
Non-Response Bias 
 T-tests and chi-square tests were conducted to determine if differences in demographic 
variables and dependent variables existed between the first 10% of respondents and the last 10% 
of respondents.  These tests failed to identify significant differences between early and late 
responders.  Summary of these analyses can be found in Tables 4-4 thru 4-9. 
 
Scale Reliability and Factor Analysis 
 
 The study consisted of seven scales.  The Cronbach’s alpha, depicted in Table 4-10, was 
used to measure reliability of the scales.  Values greater than 0.7 were considered reliable (Hair 
et al. 1998).  Social desirability was the only scale below the 0.7 threshold.      
 In a previous study (Lobb 2007) the three items shown below were added to the drug 
belief scale.  The three-item scale alone had an alpha of 0.692 in the previous study. 
   
Not valuable 1 2 3 4 5 6 7 Valuable 
Expensive 1 2 3 4 5 6 7      Cheap 
Not worth the cost 1 2 3 4 5 6 7 Worth the cost 
 
 
However, in this study the three-item scale had an alpha of .241 in the oncology scenarios and 
.272 in the allergy scenarios.  When added to the previously studied drug belief scale (Sewak 
2000, West et al. 20004, Lobb 2007), the alpha for the oncology scenarios was  reduced from 
0.923 to 0.897 and the alpha for the allergy scenarios was lowered from 0.931 to 0.912.  These 
items were not used as part of the drug belief scale.  
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Table 4-1:  Sample Description (1of 2) 
 Group % 
 Nonelderly  Elderly Total 
 n = 409 n = 421 n = 830 
Gender     
Male 29 52 40.0 
Female 71 48 60.0 
Age     
18 – 24 years 3.1  2.3 
25 – 34 years 16.4  8.4 
35 – 44 years 18.1  8.9 
45 – 54 years 26.1  14.5 
55 – 64 years 36.3  16.6 
65 years or older 0 100 49.3 
Marital Status    
Single, never married 19.7 2.9 11.4 
Unmarried couple living 
together 
6.9 2.0 
4.5 
Married 59.6 71.4 65.4 
Separated 0.7 0.2 0.5 
Divorced 10.5 13.2 11.8 
Widowed 2.1 10.3 6.1 
Decline to answer 0.5 - 0.3 
Race    
Black/African American 5.0 1.0 3.0 
Hispanic/Chicano/Latino 5.7 0.2 3.0  
Native American/Indian 0.7 0.5 0.6  
Oriental/Asian 2.9 2.2 2.5  
White/Caucasian 80.5 94.9 87.6 
Mixed race 2.4 0.2 1.3  
Other 1.2 0.2 0.7  
Decline to answer 1.7 0.7 1.2  
Religious Affiliation    
Catholic 24.9 22.7 23.9 
Jewish 3.8 10.0 6.9 
Mainline Protestant 13.3 26.2 19.6 
Evangelical Protestant 7.6 11.0 9.3 
Other 19.7 7.6 13.7 
Not affiliated 25.4 19.1 22.3 
Decline to answer 5.2 3.4  
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Table 4-2:  Sample Description (2 of 2) 
 Group % 
 Nonelderly  Elderly Total 
 n = 409 n = 421 n = 830 
Employment Status    
Employed full-time 62.9 4.6 34.2 
Employed part-time 10.7 9.8 10.2 
Not employed but 
looking for work 
2.4 0.7 1.6 
Not employed, not 
looking for work 
0.7 0.2 0.5 
Not employed, 
disabled 
1.2 0.5 0.8 
Retired 10.9 80.7 45.3 
Student 2.4 0.2 1.3 
Homemaker/housewife 8.3 2.2 5.3 
Other 0.5 1.0 0.7 
Education Status    
Some high school or 
less 
0.2 0.5 0.4 
High school graduate 10.5 9.3 9.9 
Some college 20.0 21.0 20.5 
2-year 
college/technical 
school graduate 
13.3 9.5 11.4 
4-year college 
graduate 
23.5 24.4 24.0 
Some postgraduate 
work 
8.6 9.0 8.8 
Postgraduate degree 24.0 26.2 25.1 
Household Income    
Under $15,000 0.7 0.5 .6 
$15,000 – $24,999 2.4 1.2 1.8 
$25,000 – $34,999 6.9 10.0 8.4 
$35,000 – $44,999 15.9 9.5 12.8 
$45,000 – $74,999 31.1 38.9 34.9 
$75,000 – $99,999 17.6 19.3 18.4 
$100,000 – $149,999 15.9 9.0 12.5 
$150,000 or more 6.2 5.6 5.9 
Decline to answer 0.7 0.5 4.6 
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Table 4-3:  Demographic Means 
 Group Mean 
 Nonelderly Elderly Total 
 n = 409 n = 421 n = 830 
Age 47.5 70.7 59.0 
# prescriptions purchased at the pharmacy in 
the past year 13.3 19.1 16.2 
# total persons live in household 2.42 1.85 2.1 
 
 
Table 4-4:  Non-response Bias Categorical Analysis Elderly Segment  
Sample Description (1 of 2) 
Variable First 10% Last 10%     χ2       
p-value                      (n=41)  (n=42) 
Gender      0.105          
0.75      Men 21 (51%) 23 (55%) 
     Women 20 (49%) 19 (45%) 
Marital Status 5.15           
0.398 Single, never married 1 (2%) 1 (2%) 
Unmarried couple living   
together 
0 (0%) 3 (7%) 
Married 27 (66%) 28 (67%) 
Separated 0 (0%) 1 (2%) 
Divorced 4 (10%) 4 (10%) 
Widowed 9 (22%) 5 (12%) 
     Decline to answer     
Race 4.00           
0.406 Black/African American 1 (2%) 0 (0%) 
Hispanic/Chicano/Latino 0 (0%) 1 (2%) 
Oriental/Asian 0 (0%) 1 (2%) 
White/Caucasian 39 (95%) 40 (95%) 
Other 1 (2%) 0 (0%) 
Religious Affiliation 9.93           
0.08 Catholic 7 (17%) 15 (36%) 
Jewish 3 (7%) 5 (12%) 
Mainline Protestant 15 (37%) 13 (31%) 
Evangelical Protestant 4 (10%) 4 (10%) 
Other 3 (7%) 3 (7%) 
Not affiliated 9 (22%) 2 (5%) 
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Table 4-5:  Non-response Bias Categorical Analysis Elderly Segment 
Sample Description (2 of 2) 
Variable First 10% Last 10%     χ2       
p-
value                      
(n=41)  (n=42) 
Employment Status 3.62           
0.460 Employed full-time 1 (2%) 0 (0%) 
Employed part-time 2 (5%) 5 (12%) 
Not employed, disabled 1 (2%) 0 (0%) 
Retired 35 (85%) 36 (86%) 
Homemaker/housewife 2 (5%) 1 (2%) 
Education Status 4.03          
0.546 High school graduate 7 (17%) 3 (7%) 
Some college 5 (12%) 6 (14%) 
2-year college/technical school 
graduate 
1 (2%) 4 (10%) 
4-year college graduate 14 (34%) 12 (29%) 
Some postgraduate work 4 (10%) 4 (10%) 
Postgraduate degree 10 (24%) 13 (31%) 
Household Income 14.3           
0.075 
Under $15,000 1 (2%) 0 (0%) 
$15,000 – $24,999 1 (2%) 0 (0%) 
$25,000 – $34,999 9 (22%) 1 (2%) 
$35,000 – $44,999 4 (10%) 1 (2%) 
$45,000 – $74,999 11 (27%) 20 (48%) 
$75,000 – $99,999 6 (15%) 10 (24%) 
$100,000 – $149,999 4 (10%) 3 (7%) 
$150,000 or more 2 (5%) 3 (7%) 
Decline to answer 3 (7%) 4 (10%) 
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Table 4-6:  Non-response Bias Continuous Analysis Elderly Segment  
Variable Mean 
and Std 
Error 
First 
10% 
Last 
10% 
t-
value 
p-
value 
(n=41)  (n=42) 
Age mean 72.3 70.4 
1.73 0.088 
std error 0.89 0.59 
# prescriptions purchased at 
the pharmacy in the past year 
mean 20.39 21.71 
-0.18 0.855 
std error 5.18 5.07 
# total persons live in 
household 
mean 1.78 1.88 
-0.73 0.465 
std error 0.76 0.45 
FDA trust mean 3.13 3.04 
0.654 0.515 
std error 0.098 0.098 
Trust in physician mean 2.55 2.49 
0.360 0.720 
std error 0.120 0.100 
Beliefs about the drug mean 4.81 4.78 
0.138 0.890 
std error 0.169 0.161 
Involvement in medical 
decision making 
mean 2.77 2.92 
-1.06 0.294 
std error 0.101 0.098 
Initial compliance mean 5.76 6.17 
-1.55 0.125 
std error 0.184 0.185 
Relevance and reliability of 
information from physician 
mean 3.61 3.56 
0.117 0.907 
std error 0.294 0.275 
 
Exploratory factor analysis was run on the following six scales: 
1. FDA trust 
2. Trust in physician  
3. Beliefs about the drug  
4. Involvement in medical decision making  
5. Initial compliance intention 
6. Relevance and reliability of drug information from physician. 
For the FDA trust scale, a single factor solution was obtained which accounted for 67.6% of 
variance.  The factor loadings for the single component are shown in Table 4-11. 
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Table 4-7:  Non-response Bias Categorical Analysis Non-Elderly Segment  
Sample Description (1of 2) 
Variable First 10% Last 10%     χ2       
p-value                      (n=42)  (n=43) 
Gender      0.72          
0.397 Men 12 (29%) 16 (37%) 
Women 30 (71%) 27 (63%) 
Marital Status 5.13           
0.400 Single, never married 6 (14%) 7 (16%) 
Unmarried couple living 
together 
5 (12%) 2 (5%) 
Married 27 (64%) 24 (56%) 
Divorced 3 (7%) 7 (16%) 
Widowed 0 (0%) 2 (5%) 
Decline to answer 1 (2%) 1 (2%) 
Race 3.04           
0.803 Black/African American 0 (0%) 1 (2%) 
Hispanic/Chicano/Latino 3 (7%) 3 (7%) 
Oriental/Asian 1 (2%) 1 (2%) 
White/Caucasian 35 (83%) 37 (86%) 
Mixed race 1 (2%) 1 (2%) 
Other 1 (2%) 0 (0%) 
Decline to answer 1 (2%) 0 (0%) 
Religious Affiliation 7.37           
0.288 Catholic 8 (19%) 13 (30%) 
Jewish 2 (5%) 1 (2%) 
Mainline Protestant 2 (5%) 7 (16%) 
Evangelical Protestant 5 (12%) 3 (7%) 
Other 7 (17%) 9 (21%) 
Not affiliated 15 (36%) 8 (19%) 
Decline to answer 3 (7%) 2 (5%) 
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Table 4-8:  Non-response Bias Categorical Analysis Non-Elderly Segment  
Sample Description (2 of 2) 
Variable First 10% Last 10%     χ2       
p-
value                      
(n=42)  (n=43) 
Employment Status 12.4           
0.054 Employed full-time 26 (62%) 25 (58%) 
Employed part-time 5 (12%) 4 (9%) 
Not employed but looking for 
work 
2 (5%) 0 (0%) 
Not employed, disabled 1 (2%) 0 (0%) 
Retired 1 (2%) 8 (19%) 
Student 1 (0%) 4 (9%) 
Homemaker/housewife 6 (14%) 2 (5%) 
Education Status 4.78           
0.444 High school graduate 5 (12%) 3 (7%) 
Some college 4 (10%) 9 (21%) 
2-year college/technical 
school graduate 
7 (17%) 10 (23%) 
4-year college graduate 14 (33%) 9 (21%) 
Some postgraduate work 3 (7%) 5 (12%) 
Postgraduate degree 9 (21%) 7 (16%) 
Household Income 5.66           
0.685 
Under $15,000 0 (0%) 1 (2%) 
$15,000 – $24,999 0 (0%) 1 (2%) 
$25,000 – $34,999 3 (7%) 1 (2%) 
$35,000 – $44,999 4 (10%) 8 (19%) 
$45,000 – $74,999 15 (36%) 16 (37%) 
$75,000 – $99,999 8 (19%) 6 (14%) 
$100,000 – $149,999 7 (17%) 4 (9%) 
$150,000 or more 2 (5%) 3 (7%) 
Decline to answer 3 (7%) 3 (7%) 
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Table 4-9:  Non-response Bias Continuous Analysis Elderly Segment  
Variable Mean and Std 
Error 
First 10% Last 10% t-value p-value 
(n=42)  (n=43) 
Age mean 46.1 50.8 
-1.67 0.099 std error 1.84 1.84 
# prescriptions purchased 
at the pharmacy in the past 
year 
mean 12.98 13.35 
-0.101 0.920 std error 3.27 1.8 
# total persons live in 
household 
mean 2.64 2.65 
-0.029 0.977 std error 0.236 0.169 
Trust in physician mean 2.74 2.79 
-0.36 0.72 std error 0.12 0.1 
Beliefs about the drug mean 4.55 4.64 
-0.43 0.668 std error 0.131 0.152 
Involvement in medical 
decision making 
mean 3.13 3.02 
1.07 0.288 std error 0.064 0.087 
Initial compliance mean 5.44 5.79 
-1.64 0.106 std error 0.135 0.166 
Relevance and reliability of 
information from physician 
mean 3.83 3.75 
0.249 0.804 std error 0.21 0.244 
 
 
Table 4-10:  Cronbach’s Alpha for Scales  
Scale (n = 830) # Items Value 
FDA trust 6 0.90 
Trust in physician 5 0.87 
Beliefs about the drug 8 0.83 
Involvement in medical decision making 7 0.73  
Initial compliance  4 0.92 
Relevance and reliability of information from 
physician 8 0.97 
Social desirability 10 0.63 
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Table 4-11:  Factor Loadings for FDA Trust Scale 
Items 
Component 
1 
The FDA is extremely thorough and careful. .823 
I completely trust the FDA’s decisions about 
which medical treatments are safe and effective. .894 
The FDA would never mislead me about 
anything. .844 
Sometimes the FDA cares more about what is 
convenient for them than about the patients’ 
medical needs. .534 
All in all, I trust the FDA completely. .896 
All in all, I trust completely in the FDA’s 
ability to regulate prescription drugs. .880 
             1 = Strongly Agree 5 = Strongly Disagree 
 
For the trust in physician scale, a single factor solution was obtained which accounted for 
66.0% of variance.  The factor loadings for the single component are shown in Table 4-12. 
 
Table 4-12:  Factor Loadings for Trust in Physician Scale  
Items Component 
1 
Sometimes this oncologist/allergist cares more about 
what is convenient for (him/her) than about your 
medical needs.  .669 
This oncologist/allergist is extremely thorough and 
careful.  .823 
You completely trust the oncologist/allergist’s 
decisions about which medical treatments are best 
for you.  .877 
This oncologist/allergist is totally honest in telling 
you about all of the different treatment options 
available for your condition.  .750 
All in all, you have complete trust in this 
oncologist/allergist. .917 
            1 = Strongly Agree 5 = Strongly Disagree 
 
A two-factor solution was obtained for the drug belief scale which accounted for 76% of 
variance.  The factor loadings for the two components are shown in Table 4-13. 
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A three factor solution was obtained for the involvement in medical decision making 
scale which accounted for 76% of variance.  The factor loadings for the two components are 
shown in Table 4-14. 
 
Table 4-13:  Factor Loadings for Drug Belief Scale 
Rotated Component Matrix 
Items  
Component 
1 2 
Good .758 .002 
Favorable .007 .906 
Beneficial .874 .004 
Useful .865 -.026 
Effective .907 -.025 
Necessary -.028 .905 
Safe .857 -.011 
Helpful .892 -.004 
    *7-point semantic scale 
 
For the initial compliance intention scale, a single factor solution was obtained which 
accounted for 81.0% of variance.  The factor loadings for the single component are shown in 
Table 4-15. 
For the relevance and reliability scale, a single factor solution was obtained which 
accounted for 84.8% of variance.  The factor loadings for the single component are shown in 
Table 4-16.  Based on these loadings, all items were summed to form the scale. 
 
Social Desirability Assessment 
 
 Pearson’s correlation coefficient was used as the measure of association between the 
other scales and the Marlowe-Crowne Social Desirability Scale (Strahan and Gerbasi 1972), 
despite its low Cronbach’s alpha (0.63).  Although statistically significant, the apparent risk of 
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social desirability was deemed limited.  Table 4-17 summarizes the findings of the scales’ 
significant correlations (p < 0.05).  
 
Table 4-14:  Factor Loadings for Involvement in Medical Decision Making Scale 
Rotated Component Matrix 
Items  
Component 
1 2 3 
I will always follow this oncologist’s/allergist’s 
recommendations about treatment. .775 .016 .230 
It is better to rely on the expert judgment of this 
oncologist/allergist than to rely on common sense in 
taking care of my own body.  .587 .089 .560 
It is better to seek professional help than to try to treat 
myself.  .135 .005 .908 
Concerning my medical care, I should take complete 
control.  .013 .841 .186 
Concerning my medical care, the oncologist/allergist 
should take complete control.  .789 .068 .135 
In my future visits with the oncologist/allergist, I 
believe I will make all of the final decisions.  .197 .801 -.142 
In my future visits with the oncologist/allergist, I 
believe the oncologist should take the initiative and 
decide what is best for me.  .826 .211 -.001 
1 = Strongly Agree 5 = Strongly Disagree 
 
Table 4-15:  Factor Loadings for Initial Compliance Intention Scale 
Items 
Component 
1 
No chance .929 
Likely .813 
Not possible .943 
Certain not to purchase .910 
   *9-point semantic scale 
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                        Table 4-16:  Factor Loadings for Relevance and Reliability  
     Drug Information from Physician Scale 
Items 
Component 
1 
Dependable .914 
Helpful .936 
Important .888 
Consistent  .908 
Meaningful .947 
Relevant .933 
Reliable .917 
Useful .924 
   *7-point semantic scale 
 
Table 4-17:  Social Desirability Scale Significant Correlations  
Scale n Sig. (2-tailed) 
Pearson’s 
Correlation 
Trust in physician 830 0.015 -0.085 
Beliefs about the drug  830 0.002 .107 
 
 
Trust in the FDA 
 The trust expressed in the FDA is weak at best and did not differ across age groups 
(Table 4-18).  While there is slight agreement with the FDA being extremely thorough and 
careful (mean 2.61, standard deviation = 0.896), there is similar agreement that sometimes the 
FDA is more concerned about itself than about patients’ medical needs (mean 2.73, standard 
deviation = 0.931). 
 
General Beliefs of Off-Label Prescribing 
 The items in Table 4-19 were created to examine patient perceptions of off-label 
prescriptions, a current void in the off-label literature.  Based on a five-point Likert scale, the 
reported means are close to the middle of the scale.  Only three items had differences from the 
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midpoint greater than 0.5.  Most respondents assumed (1) the majority of the prescriptions in the 
US were prescribed on-label (mean = 2.19, standard deviation = 0.696) and (2) most physicians 
 
Table 4-18:  Trust in FDA 
  Nonelderly Elderly 
Total (n = 
830) 
Item Mean Mean Mean SD 
1. The FDA is extremely thorough and careful. 2.61 2.62 2.61 .896 
2. I completely trust the FDA’s decisions about 
which medical treatments are safe and effective. 2.93 2.94 2.93 .959 
3. The FDA would never mislead me about 
anything. 3.17 3.20 3.19 .933 
4. Sometimes the FDA cares more about what is 
convenient for them than about the patients’ medical 
needs. 2.73 2.74 2.73 .931 
5. All in all, I trust the FDA completely. 3.06 3.09 3.07 .960 
6. All in all, I trust completely in the FDA’s ability 
to regulate prescription drugs. 2.95 3.00 2.97 0.898 
1 = Strongly Agree 5 = Strongly Disagree 
*p < 0.05 
 
 
knew whether the drug was FDA-approved for the indication for which it was prescribed (mean 
= 2.26, standard deviation = 0.782).  Respondents believed their own prescriptions were FDA 
approved for the disease for which they use them (mean = 2.19, standard deviation = 0.898).  
There were statistically significant differences (p<0.05) among the elderly and nonelderly, with 
most differences revealing a tendency for younger respondents (1) to assume more use of off-
label prescribing (items 1, 6, 12, and 13) and (2) potentially being more accepting of the concept 
and potential gains from off-label use (items 7, 8, and 9). 
 
Manipulation Check 
 
This study used a 2 × 2 × 2 design to assess the effects of off-label and on-label 
prescribing in two different levels of disease criticality and in two different norms of off-label  
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Table 4-19:  General Beliefs of Off-Label Prescribing 
  Nonelderly Elderly 
Total (n = 
830) 
Item Mean Mean Mean SD 
1.  I believe the majority of prescriptions in the US are 
prescribed on label to treat diseases for which they are FDA 
approved. 
2.25* 2.13* 2.19 0.696 
2.  I believe it is safe to use FDA-approved drugs off label 
to treat other diseases than for what they were originally 
approved.  2.76 2.76 2.76 0.838 
3.  I believe most physicians know when a drug is FDA 
approved or not approved to treat the disease in which they 
are prescribing it. 2.30 2.21 2.26 0.782 
4.  I believe insurance companies check to make sure the 
drug prescribed by the physician is being used on label to 
treat a disease for which it has been FDA approved.  2.95 2.92 2.94 0.996 
5.  I believe pharmacists check to make sure the drug 
prescribed by the physician is being used on label to treat a 
disease for which it has been FDA approved.  
2.89 2.79 2.84 0.957 
6.  I believe all of the drugs I take are on label – FDA 
approved for the disease in which I use the drugs.  
2.32* 2.06* 2.19 0.898 
7.  I believe drugs that are used on label – FDA approved 
for a disease – are always more effective than drugs that are 
not FDA approved for that disease.  
3.06* 2.91* 2.99 0.892 
8.  I believe drugs that are on label – FDA approved for a 
disease – are always safer than drugs that are off label – not 
FDA approved for that disease.  
2.93* 2.72* 2.83 0.917 
9.  I only want to be prescribed drugs that are on label – 
FDA approved to treat the specific disease I have.  2.85* 2.60* 2.73 0.994 
10.  I believe doctors who prescribe drugs off label for 
diseases for which the drugs are not FDA approved are 
superior doctors.  
3.28 3.38 3.33 0.722 
11.  I believe only doctors who prescribe drugs off label – 
for diseases for which the drugs are not FDA approved – 
only do so because it is the best option for their patient.  2.63 2.62 2.62 0.812 
12.  I believe doctors only prescribe drugs off label – that 
are not FDA approved – for very rare diseases, not for more 
common ones.  
3.01* 2.78* 2.90 0.868 
13.For children, I believe doctors only prescribe drugs on 
label – for diseases for which the drugs are FDA approved.  2.72* 2.61* 2.66 0.839 
1 = Strongly Agree 5 = Strongly Disagree  
*p < 0.05 
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use based on the separation of beliefs between the diseases regarding potential harm and the 
negative impact on the respondent’s life.  As shown in Table 4-20, the disease criticality 
manipulation was determined to be effective.  
 
Table 4-20:  Disease Criticality Manipulation Check 
After reading each statement, rate how 
much you agree or disagree with each 
statement.  When answering these 
survey questions, I assume… Disease Mean n 
Std. 
Deviation 
it is important to treat the ____ 
described in the scenario. 
oncology 1.54* 412 0.716 
allergy 2.02* 418 0.687 
the ___ described in the scenario 
will be extremely harmful to my 
health without the drug treatment.  
oncology 1.60* 412 0.779 
allergy 3.04* 418 0.974 
having the ___ described in the 
scenario will NOT have a large 
negative effect on my life. 
oncology 4.03* 412 1.02 
allergy 2.67* 418 0.908 
*Significance  p < 0.05   
1 = Strongly Agree 5 = Strongly Disagree 
 
 
Research Questions and Propositions 
  
 The following section shows the results used to examine the study’s 3 research questions, 
13 propositions, and 2 hypotheses. 
 
Research Question 1.  What are the roles of disease criticality (DISCRIT), FDA approval status 
of the prescribed drug (FDASTAT), and the “normal” level of off-label use (OFFUSELVL) in 
beliefs formed about the prescribed drug, level of trust in the physician, level of involvement in 
medical decision making, and intentions of initial compliance? 
 
Exploratory multiple regressions 
 Exploratory multiple regressions were used to measure the effects of disease state, 
normal level of FDA-approved product use, and FDA approval status on beliefs of the drug 
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initial compliance intent, trust in the physician, and involvement in medical decision making.  
The ability to model interactions, including two-way and three-way interactions, and identify 
issues such as multicollinearity was critical.  The variables including interactions were all 
entered in one step, and the interactions were removed as they were found not to be significant.   
 
Initial compliance intention 
 The relationships among the variables were first assessed with initial compliance as the 
dependent variable using the following equation: 
 
Initial compliance = DISCRIT + OFFUSELVL + FDASTAT + DISCRIT*OFFUSELVL + 
DISCRIT*FDASTAT + OFFUSELVL*FDASTAT + DISCRIT*OFFUSELVL*FDASTAT 
 
After it was revealed that the three-way interaction was not significant (p > 0.05), it was removed 
to assess the main effects and the two-way interactions.  Neither interaction was significant; thus, 
they were removed to assess the main effects in the following equation: 
 
Initial compliance = DISCRIT + OFFUSELVL + FDASTAT  
 
Here the FDA status of the drug and the criticality of the disease were significant (Table 4-21), 
showing compliance was increased with on-label prescribing and in the more critical disease 
scenario. 
 
Table 4-21.  Main Effects Multiple Regression Model for Initial Compliance 
 
Unstandardized 
Coefficients 
Standardized 
Coefficients t Sig. 
 B Std. Error Beta   
(Constant) 5.705 .318   17.927 .000 
DISCRIT -.414 .120 -.116 -3.464 .001 
OFFUSELVL -.034 .120 -.010 -.286 .775 
FDASTAT .936 .120 .261 7.829 .000 
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Involvement in medical decision making 
 Involvement in medical decision making followed a pattern similar to the analysis of 
initial compliance after first using this equation to assess the interactions: 
 
Involvement in medical decision making = DISCRIT + OFFUSELVL + FDASTAT + 
DISCRIT*OFFUSELVL +  DISCRIT*FDASTAT + OFFUSELVL*FDASTAT + 
DISCRIT*OFFUSELVL*FDASTAT 
 
The three-way interaction was not significant (p > 0.05) and was removed to assess the main 
effects and the two-way interactions.  Neither interaction was significant; thus, they were 
removed to assess the main effects in the following equation: 
 
Involvement in medical decision making = DISCRIT + OFFUSELVL + FDASTAT  
 
Although the FDA status of the drug and the criticality of the disease were significant (Table 4-
22), the relationship was the opposite direction as seen with initial compliance intention.  Here 
an increase in involvement was observed with off-label prescribing and in the less critical disease 
scenario.  
 
Table 4-22:  Main Effects Multiple Regression Model for Involvement 
in Medical Decision Making 
 
Unstandardized 
Coefficients 
Standardized 
Coefficients t Sig. 
 B Std. Error Beta   
(Constant) 2.994 .102   29.236 .000 
DISCRIT .136 .039 .120 3.529 .000 
OFFUSELVL .016 .039 .014 .409 .683 
FDASTAT -.174 .038 -.154 -4.511 .000 
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Trust in Physician  
 The relationships among the variables were assessed with trust in the physician as the 
dependent variable using the following equation: 
 
Trust in the physician = DISCRIT + OFFUSELVL + FDASTAT + DISCRIT*OFFUSELVL 
+ DISCRIT*FDASTAT + OFFUSELVL*FDASTAT + 
DISCRIT*OFFUSELVL*FDASTAT 
 
The three-way interaction was not significant (p > 0.05) and was removed to assess the main 
effects and the two-way interactions shown in the following equation: 
 
Trust in the physician = DISCRIT + OFFUSELVL + FDASTAT + DISCRIT*OFFUSELVL 
 
+ DISCRIT*FDASTAT + OFFUSELVL*FDASTAT  
 
 
Here the FDASTAT*DISCRIT interaction was significant (Table 4-23) used in the final 
equation: 
 
Trust in the physician = DISCRIT + OFFUSELVL + FDASTAT + DISCRIT*FDASTAT  
 
Given the significance of the interaction, a step-down analysis examined the simple effects 
using t tests as shown in Table 4-24.   
 
Table 4-23:  Main Effects Multiple Regression Model for Trust in the Physician 
 
Unstandardized 
Coefficients 
Standardized 
Coefficients t Sig. 
 B Std. Error Beta   
(Constant) 2.304 .246   9.351 .000 
DISCRIT .449 .149 .323 3.014 .003 
OFFUSELVL .040 .047 .029 .847 .397 
FDASTAT .095 .149 .068 .632 .527 
FDASTATXDISCRIT -.249 .094 -.390 -2.637 .009 
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Table 4-24:  Step-Down Analysis of Simple Effects (t tests) for Trust in the Physician 
 t Sig. Means 
FDASTAT (off-label) 
      DISCRIT  
-2.92 .004 
2.7 
oncology 
2.9 
allergy 
FDASTAT (on-label) 
      DISCRIT  
0.762 .446 
2.5 
oncology 
2.5 
allergy 
DISCRIT (oncology)          
      FDASTAT  
2.214 .027 
2.7  
off-label 
2.5  
on-label 
DISCRIT (allergy)  
      FDASTAT  
6.289 < 0.000 
2.9  
off-label 
2.5  
  on-label 
 
This shows the magnitude of the effect of off-label prescribing was moderated by the disease 
criticality.  Respondents had a greater decrease in trust in the physician when receiving an off-
label prescription in a less critical disease state than in a more critical disease state. 
 
Belief measures about the drug 
 The relationships among the variables were assessed with trust in the physician as the 
dependent variable using the following equation: 
 
Beliefs of the drug = DISCRIT + OFFUSELVL + FDASTAT + DISCRIT*OFFUSELVL + 
DISCRIT*FDASTAT + OFFUSELVL*FDASTAT + DISCRIT*OFFUSELVL*FDASTAT 
 
The three-way interaction was not significant (p > 0.05) and was removed to assess the main 
effects and the two-way interactions shown in the following equation: 
 
Beliefs of the drug = DISCRIT + OFFUSELVL + FDASTAT + DISCRIT*OFFUSELVL 
 
+ DISCRIT*FDASTAT + OFFUSELVL*FDASTAT  
 
 
Here the FDASTAT*DISCRIT interaction was significant (Table 4-25) used in the final 
equation: 
 
 
Beliefs of the drug = DISCRIT + OFFUSELVL + FDASTAT + DISCRIT*FDASTAT  
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Table 4-25:  Main Effects Multiple Regression Model for Beliefs of the Drug 
 
Unstandardized 
Coefficients 
Standardized 
Coefficients t Sig. 
 B Std. Error Beta   
(Constant) 4.997 .410   12.191 .000 
DISCRIT -.489 .248 -.214 -1.973 .049 
OFFUSELVL .027 .078 .012 .346 .729 
FDASTAT -.107 .249 -.047 -.430 .668 
FDASTATXDISCRIT .317 .157 .303 2.023 .043 
 
 
Given the significance of the interaction, a step-down analysis examined the simple effects using 
t tests as shown in Table 4-26.   
 
Table 4-26:  Main Effects Multiple Regression Model for Beliefs of the Drug 
 t Sig. Means 
FDASTAT (off-label) 
      DISCRIT  
 1.648 0.100 
4.8 
oncology 
4.6 
allergy 
FDASTAT (on-label) 
      DISCRIT  
-1.237 
0.217 
 
5.0 
oncology 
5.1 
allergy 
DISCRIT (oncology)          
      FDASTAT  
-1.906 0.057 
4.8 
off-label 
5.0 
on-label 
DISCRIT (allergy)  
      FDASTAT  
-4.757 < 0.000 
4.6 
off-label 
5.1 
on-label 
 
This shows that the effect of off-label prescribing was moderated by the disease criticality.   
Respondents had a significant loss in beliefs in the drug when receiving an off-label prescription 
compared to on-label drug only in the less critical disease state (allergy).   
 
Propositions 1- 12 
 In addition to being informed by the exploratory multiple regressions, simple t tests were 
used to determine if the 2 group means were different for each of the 12 research propositions.   
 
P1 The prescribing of an FDA-approved drug leads to a greater likelihood of patient initial 
compliance intention with a prescription than prescribing off-label.     
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 As shown in the regression analysis, off-label prescribing did decrease the initial 
compliance intention.  It was also assessed using a simple t test showing a significant greater 
compliance intention with an on-label prescription (p < 0.000).  The additional support for 
Proposition 1 is displayed in Table 4-27.   
 
Table 4-27:  T-Test of Initial Compliance Intention* by FDA Approval Status 
FDA Status n Mean s.d. 
Off-label 415 5.97 1.81 
On-label 415 6.90 1.65 
    *9-point semantic scale 
 
P2 The prescribing of an off-label FDA-approved drug when the norm is to use FDA-
approved products leads to a lower likelihood of patient initial compliance with a 
prescription than prescribing an FDA-approved drug.  
 
 The simple t test showed a significant decrease in compliance intention with an off-label 
prescription (p < 0.000) when the norm (75%) was to use an on-label drug.  The support for 
Proposition 2 is displayed in Table 4-28.   
 
Table 4-28:  T-Test of Initial Compliance Intention* by FDA Approval 
Status When Norm Is to Use On-Label 
FDA Status N Mean s.d. 
Off-label 204 6.04 1.80 
On-label 208 6.81 1.62 
    *9-point semantic scale  
 
P3 The prescribing of an off-label FDA-approved drug in a more critical disease leads to a 
greater likelihood of patient initial compliance with a prescription than in a less critical 
disease.   
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 The simple t test showed a significant decrease in compliance intention with an off-label 
prescription (p = 0.004) in a less critical disease state.  The support for Proposition 3 is displayed 
in Table 4-29.   
 
Table 4-29:  T-Test of Initial Compliance Intention* by Disease Criticality When Receiving 
Off-Label Prescription 
Disease 
Criticality n Mean s.d. 
Oncology 206 6.22 1.87 
Allergy 209 5.72 1.72 
    *9-point semantic scale  
 
P4 The prescribing of an FDA-approved drug leads to a greater trust in the physician than 
prescribing off-label.   
 
 As shown in the regression analysis, off-label prescribing did decrease trust in the 
physician; however, the relationship was shown to be colored by disease criticality as well.  The 
proposition was also assessed using a simple t test showing a significant decrease in trust in the 
physician when writing an off-label prescription (p < 0.000).  The additional support for 
Proposition 4 is displayed in Table 4-30.   
 
Table 4-30:  T-Test of Trust in Physician* by FDA Approval Status 
FDA Status n Mean s.d. 
Off-label 415 2.76 0.70 
On-label 415 2.48 0.66 
    *1 = Strongly Agree 5 = Strongly Disagree 
 
P5 The prescribing of an off-label FDA-approved drug when the norm is to use FDA-
approved products leads to lower trust in the physician than prescribing an FDA-
approved drug. 
 
 70 
 The simple t test showed a significant decrease in trust in the physician with an off-label 
prescription (p < 0.000) when the norm (75%) was to use an on-label drug.  The support for 
Proposition 5 is displayed in Table 4-31.   
 
Table 4-31:  T-Test of Trust in Physician* by FDA Approval Status 
When Norm Is to Use On-Label 
FDA Status n Mean s.d. 
Off-label 204 2.77 0.74 
On-label 208 2.51 0.66 
    *1 = Strongly Agree 5 = Strongly Disagree 
 
P6 The prescribing of an off-label FDA-approved drug in a less critical disease leads to a 
lower trust in the physician than in a more critical disease. 
 
 The simple t test showed a significant decrease in trust in the physician with an off-label 
prescription (p = 0.004) in a less critical disease state.  The support for Proposition 3 is displayed 
in Table 4-32.   
 
Table 4-32:  T-Test of Trust in the Physician* by Disease Criticality 
When Receiving Off-Label Prescription 
Disease 
Criticality n Mean s.d. 
Oncology 206 2.66 0.71 
Allergy 209 2.86 0.69 
    *1=Strongly Agree 5 = Strongly Disagree 
 
P7 There is no difference in the likelihood of patient involvement in medical decision 
making when an FDA-approved drug is prescribed than when an off-label drug is 
prescribed. 
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 The proposition was assessed using a simple t test showing a significant increase in 
patient involvement in medical decision making when writing an off-label prescription (p < 
0.000).  The significant difference refutes Proposition 7 and is displayed in Table 4-33.     
 
Table 4-33:  T-Test of Patient Involvement in Medical Decision Making* 
by FDA Approval Status 
FDA Status n Mean s.d. 
Off-label 415 3.05 0.54 
On-label 415 2.88 0.57 
    *1 = Strongly Agree 5 = Strongly Disagree   
 
P8 There is no difference in the likelihood of patient involvement in medical decision 
making when being prescribed an FDA-approved drug when the norm is to use FDA-
approved products than prescribing an off-label drug.  
 
 The simple t test showed a significant increase in involvement in medical decision 
making with an off-label prescription (p = 0.010) when the norm (75%) was to use an on-label 
drug.  The significant difference refutes Proposition 8 and is displayed in Table 4-34.   
 
Table 4-34:  T-Test of Patient Involvement in Medical Decision Making* by FDA 
Approval Status When Norm Is to Use On-Label 
FDA Status n Mean s.d. 
Off-label 211 3.02 0.52 
On-label 207 2.89 0.56 
    1 = Strongly Agree 5 = Strongly Disagree 
 
P9 There is no difference in the likelihood of patient involvement in medical decision 
making when being prescribed an off-label drug in a critical disease than in a less critical 
disease.  
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 The simple t test showed a significant increase in involvement in medical decision 
making with an off-label prescription (p = 0.001) in a less critical disease state.  The significant 
difference refutes Proposition 9 and is displayed in Table 4-35.  
 
Table 4-35:  T-Test of Patient Involvement in Medical Decision Making* 
by Disease Criticality When Receiving Off-Label Prescription 
Disease 
Criticality n Mean s.d. 
Oncology 206 2.96 0.53 
Allergy 209 3.14 0.54 
    *1=Strongly Agree 5 = Strongly Disagree 
 
P10 The prescribing of an FDA-approved drug leads to stronger positive beliefs about the 
drug than prescribing off-label. 
 
 As shown in the regression analysis, off-label prescribing weakened beliefs in the drug, 
but only in the less critical disease.  The proposition was also assessed using a simple t test 
showing significantly weakened beliefs in the drug when writing an off-label prescription (p < 
0.000).  The additional support for Proposition 10 is displayed in Table 4-36.   
 
Table 4-36:  T-Test of Beliefs About the Drug* by FDA Approval Status 
FDA Status n Mean s.d. 
Off-label 415 4.67 1.07 
On-label 415 5.04 1.19 
    *7-point semantic scale 
 
P11 The prescribing of an off-label FDA-approved drug when the norm is to use FDA-
approved products leads to weaker positive beliefs about the drug than prescribing an 
FDA-approved drug. 
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 The simple t test showed a significant weakening of beliefs in the drug (p < 0.000) when 
the norm (75%) was to use an on-label drug.  The support for Proposition 11 is displayed in 
Table 4-37.   
 
Table 4-37:  T-Test of Beliefs About the Drug* by FDA Approval Status 
When Norm Is to Use On-Label 
FDA Status n Mean s.d. 
Off-label 211 4.60 1.05 
On-label 207 5.08 1.15 
    *7-point semantic scale 
 
P12 The prescribing of an off-label FDA-approved drug in a less critical disease leads to 
weaker positive beliefs about the drug than in a more critical disease. 
 
 The simple t test did not show a significant difference in beliefs in the drug with an off-
label prescription (p = .100) in a less critical disease state.  The significant difference refutes 
Proposition 9 and is displayed in Table 4-38.  
 
Table 4-38:  T-Test of Beliefs About the Drug* by Disease Criticality  
When Receiving Off-Label Prescription 
Disease 
Criticality n Mean s.d. 
Oncology 206 4.76 1.10 
Allergy 209 4.59 1.03 
    *7-point semantic scale 
 
Research Question 2.  What are the roles of relevance and reliability judgments of the physician-
provided information in beliefs formed about a prescribed drug and the intentions of initial 
compliance? 
 
H1 The higher the judged relevance and reliability of the physician-provided information are, 
the stronger the positive beliefs formed about the prescription product will be. 
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H2 The higher the judged relevance and reliability of the physician-provided information are, 
the greater the initial compliance intention will be. 
 
A bivariate correlational analysis (Table 4-38) supported hypotheses 1 and 2.  A 
significant Pearson’s correlation coefficient (p < 0.000) demonstrated the association between 
the physician-provided information relevance and reliability and (1) beliefs about the medication 
and (2) initial compliance intention.   
 
Table 4-39:  Hypotheses 1 and 2 Correlation with Relevance and 
Reliability of MD Information* 
Scale n Sig. (2-tailed) 
Pearson’s 
Correlation 
Beliefs about the drug 830 < 0.000 0.510 
Initial compliance intention 830 < 0.000 -0.601** 
  *7-point semantic scale 
  **Note: negative correlation is due to the reverse orientation of the scale    
  
 
Research Question 3.  How do the roles of these elements differ in a population of elderly 
patients when compared to younger patients? 
The propositions below were tested using a series of independent t tests to identify age-
related differences:  
P13 Elderly (≥ 65 years old) patients differ from younger patients in responses to behavior of 
off-label use, trust in physicians, and initial compliance intentions. 
P13oA In the same off-label scenarios, elderly patients do not differ from younger patients in the 
strength of the beliefs formed about the prescription. 
P13oB In the same off-label scenarios, elderly patients do not differ from younger patients in 
their initial compliance intentions measured by a multi-item scale. 
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P13oC In the same off-label scenarios, elderly patients do not differ from younger patients in 
their judgments of relevance and reliability of physician-provided information. 
P13oD In the same off-label scenarios, elderly patients do not differ from younger patients in 
their trust in physicians. 
P13oE In the same off-label scenarios, elderly patients do not differ from younger patients in 
their involvement in medical decision making. 
 Based on the results shown in Table 4-40, it appears that the elderly (≥ 65 years old) do 
differ from the nonelderly (< 65 years old) on all variables tested.  Proposition 13 is supported by 
all relevant variable analyses (Table 4-41).  The elderly appear to be slightly more trusting of 
physicians and positive in their beliefs about drugs as well as have higher intentions of initial 
compliance based on the scenarios.  The elderly had lower intentions of involvement in the 
medical decision making.  The higher trust in the physician and lower intentions to be involved 
in the decision making were likely supported by the elderly finding the information from the 
physician more relevant and reliable. 
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Table 4-40:  Final Proposition 13 Test Results 
Variables Tested Age n Mean 
Std. 
Deviation 
Beliefs about the drug
1
 
Elderly 409 4.96* 1.20386 
Nonelderly 421 4.76* 1.07785 
Initial compliance intention
2
 
Elderly 409 5.91* 1.13382 
Nonelderly 421 5.73* .97099 
Relevance and reliability of physician-
provided information
2
 
Elderly 409 3.42* 1.73946 
Nonelderly 421 3.77* 1.54225 
Trust in physicians
3
 
Elderly 409 2.57* .72111 
Nonelderly 421 2.67* .66756 
Involvement in medical decision 
making
3
 
Elderly 409 2.87* .59241 
Nonelderly 421 3.05* .52163 
*Significance  p < 0.05    
1
7-point semantic scale  
2
7-point semantic scale  
3
1 = Strongly Agree 5 = Strongly Disagree 
   
 
Table 4-41.  Final Proposition 13 Summary 
Proposition Supported? 
(Y/N) 
P13  Elderly (≥ 65 years old) patients differ from younger patients (< 65 
years old) in responses to behavior of off-label use, trust in physicians, 
and initial compliance intentions. 
Yes 
P13oA  In the same off-label scenarios, elderly patients do not differ from 
younger patients in the strength of the beliefs formed about the 
prescription. 
No 
P13oB  In the same off-label scenarios, elderly patients do not differ from 
younger patients in their initial compliance intentions measured by a 
multi-item scale. 
No 
P13oC  In the same off-label scenarios, elderly patients do not differ from 
younger patients in their judgments of relevance and reliability of 
physician-provided information. 
No 
P13oD  In the same off-label scenarios, elderly patients do not differ from 
younger patients in their trust in physicians. 
No 
P13oE  In the same off-label scenarios, elderly patients do not differ from 
younger patients in their involvement in medical decision making. 
No 
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Table 4-42 is a summary of the support for all of the study’s propositions and hypotheses. 
 
Table 4-42:  Final Proposition (1-13)/Hypotheses (1-2) Support Summary 
Proposition/Hypothesis Supported? 
(Y/N) 
P1 The prescribing of an FDA-approved drug leads to a greater likelihood of 
patient initial compliance intention with a prescription than prescribing off-label. 
Yes 
P2 The prescribing of an off-label FDA-approved drug when the norm is to use 
FDA-approved products leads to a lower likelihood of patient initial compliance 
with a prescription than prescribing an FDA-approved drug. 
Yes 
P3 The prescribing of an off-label FDA-approved drug in a more critical disease 
leads to a greater likelihood of patient initial compliance with a prescription than 
in a less critical disease. 
Yes 
P4 The prescribing of an FDA-approved drug leads to a greater trust in the 
physician than prescribing off-label. 
Yes 
P5 The prescribing of an off-label FDA-approved drug when the norm is to use 
FDA-approved products leads to lower trust in the physician than prescribing an 
FDA-approved drug. 
Yes 
P6 The prescribing of an off-label FDA-approved drug in a less critical disease 
leads to a lower trust in the physician than in a more critical disease. 
Yes 
P7 There is no difference in the likelihood of patient involvement in medical 
decision making when an FDA-approved drug is prescribed than when an off-
label drug is prescribed. 
No 
P8 There is no difference in the likelihood of patient involvement in medical 
decision making when being prescribed an FDA-approved drug when the norm is 
to use FDA-approved products than prescribing an off-label drug. 
No 
P9 There is no difference in the likelihood of patient involvement in medical 
decision making when being prescribed an off-label drug in a critical disease than 
in a less critical disease. 
No 
P10 The prescribing of an FDA-approved drug leads to stronger positive beliefs 
about the drug than prescribing off-label. 
Yes 
P11 The prescribing of an off-label FDA-approved drug when the norm is to use 
FDA-approved products leads to weaker positive beliefs about the drug than 
prescribing an FDA-approved drug. 
Yes 
P12 The prescribing of an off-label FDA-approved drug in a less critical disease 
leads to weaker positive beliefs about the drug than in a more critical disease. 
Yes 
H1 The higher the judged relevance and reliability of the physician-provided 
information are, the stronger the positive beliefs formed about the prescription 
product will be. 
Yes 
H2 The higher the judged relevance and reliability of the physician-provided 
information are, the greater the initial compliance intention will be. 
Yes 
P13  Elderly (≥ 65 years old) patients differ from younger patients (< 65 years old) 
in responses to behavior of off-label use, trust in physicians, and initial 
compliance intentions. 
Yes 
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CHAPTER V 
DISCUSSION AND IMPLICATIONS 
 
 Off-label prescribing is common, especially in certain disease states (Radley et al. 2006, 
Peppercorn 2008, Soares 2005, Tarbarrok 2000, Bazzano 2009, Pathak et al. 2010), yet no 
research exists that assesses the effect of non-FDA-approved uses of pharmaceuticals on patient 
decision making.  This study seeks to begin to fill that void.  A survey using an online panel 
obtained 830 responses between 2 age groups, elderly (≥ 65) and nonelderly (< 65).  This chapter 
discusses the findings and the implications of this study, which sought to understand the effects 
of off-label prescribing on patient decision making. 
 
Off-Label Prescribing Beliefs and Trust in the FDA 
In general, respondents did not have strong opinions regarding off-label use.  The means 
remained close to the midpoint of the scales.  The responses reveal that most assume the majority 
of prescriptions in the US were prescribed on-label and that most assume physicians know when 
the drug is FDA-approved for the indication for which it is prescribed.  The respondents appear 
to believe their own prescriptions were FDA approved for the disease for which they use them 
(mean = 2.19).  When respondents were asked about their beliefs that pharmacists and insurance 
companies were monitoring off-label use, the responses were neutral.  Ignorance may be 
affecting their opinions and thus limiting the direction and magnitude.  Similar results were 
found in the only research identified that looked at patient perceptions of off-label use.  Lenk et 
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al. (2009) studied the parents of 51 healthy children and 43 children with renal disease in 
Germany.  “Knowledge about the practise of off-label use [was] generally poor in both groups. 
Surprisingly, this [was] also true for the parents of children with chronic disease.  Nine percent 
of the parents of chronically ill children and 20% of the parents of healthy children would refuse 
treatment with an off-label drug” (p. 1743).   
There were statically significant differences between the elderly and nonelderly regarding 
their beliefs about off-label prescribing.  Most differences revealed a tendency for younger 
respondents to (1) assume more use of off-label prescribing in general and (2) acknowledge the 
existence of potential gains of off-label use and be more accepting of the concept of off-label 
use. 
Trust in the FDA was also measured with no demonstrated difference between the age 
groups.  It is interesting to note how the items all scored around the midpoint, with no mean 
being greater than a distance of 0.5 away from the midpoint on a 5-point scale.  Directionally 
there is trust in the FDA; however, this trust is weak at best.  This is slightly different from what 
previous research has shown:  despite 93% of patients being confident about the safety and 
effectiveness of drugs approved for use in the US, roughly one third to over one half feel 
negatively about how the FDA is doing its perceived job (Pricewaterhouse Coopers 2010, Harris 
Interactive 2008).   
As with other results in the study, the magnitude of the off-label beliefs and trust in the 
FDA are not strong, but the directions are interesting and generally apply to the hypothesized 
behavior and conceptual framework set out in Chapter II.  
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Trust in Physicians 
Some have described patient trust as “a collective good, similar to ‘social capital,’ that is 
necessary for an effective health care system” (Thom et al. 2004, p. 126).  Trust in the physician 
can affect initial compliance via willingness to pay.  Lower levels of trust in physician were 
associated with an increased likelihood of forgoing medications with higher out-of-pocket costs.  
Only in the context of low levels of trust in physicians did the researchers find an association 
with low income and cost-related adherence.  Researchers concluded that a “trusting physician 
relationship may moderate the impact of cost pressures on patients’ medication adherence.   
More generally, addressing noncost barriers to adherence may reduce rates of cost-related 
medication underuse” (Piette et al. 2005, p. 1749).  
Despite the importance of trust in the health care system and the readily identifiable 
challenges an off-label prescription could potentially cause, no studies have measured the 
impact.  In this study, the scale selected (Dugan et al. 2004) was specifically developed for 
measuring trust in an individual physician—not trust in the medical profession—so the impact of 
the off-label prescription could be directly attributed to the prescribing physician. 
In the scenarios studied, off-label prescribing did significantly decrease trust in the 
physician.  Disease critically moderated this relationship.  Respondents had a greater decrease in 
trust in physicians when receiving an off-label prescription in a less critical disease state than in a 
more critical disease state.  Off-label prescribing seems to have the potential for a costly impact 
on the health care system’s “social capital,” trust in the prescribing physician. 
Given the gap that likely exists between the tested scenarios of cancer and allergies, one 
is left to question the relationship between off-label prescribing and less “urgent” diseases (e.g., 
hypertension) or diseases in which some patients have more “disease and treatment knowledge,” 
such as sometimes found in rare diseases.   
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Involvement in Decision Making 
 
Trachtenberg and colleagues (2005, p. 345) describe the challenging relationship between 
trust and involvement in medical decision making: 
Both patient trust and active patient involvement are desirable in their own right and 
because they are associated with improved health outcomes.  Paradoxically, however, it 
might be thought that these 2 attributes are in sharp conflict. 
Patient trust might be more consistent with a deferential style of patient-physician 
interaction in which patients are passive, in contrast to assertive patient questioning or 
limitation of physician authority which might be indicative of patient distrust.   
Their research with American adult patients (n = 533) found that the most significant 
predictor of patients’ preferred role in medical decision making was trust in the medical 
profession (not the specific physician).  Although that finding suggests that involvement in 
decision making may be independent of trust in the specific physician, it seems that when trust 
was reduced in the prescribing scenarios, involvement in decision making increased at least 
temporarily.  The involvement increase with off-label prescribing was especially noted in the less 
critical disease scenario.  This suggests that when patients perceive something is amiss or may go 
awry, they feel they must monitor it more closely, especially in a disease state for which they 
may have more knowledge (e.g., allergies versus cancer). 
These results support previous research which found patients’ desire to be involved in 
decision making and the treatment process to be inversely proportional to the disease criticality 
in numerous diseases (Levinson et al. 2005, Arora et al. 2000). 
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Belief About the Drug 
 In this study, univariate analysis showed a significant decrease in beliefs formed about 
the drug.  A significant decrease in beliefs about the drug was observed in multivariate analysis 
when receiving an off-label prescription compared to on-label drug, but only in the less critical 
disease state (allergy).  Further research is needed to understand the cause for this difference as 
well as means to avoid this lowering of beliefs.  It should be noted that trust in the physician 
diminished significantly in both disease states, albeit more in allergies.  Trust in the physician, 
therefore, was arguably put at greater risk with off-label prescribing than positive beliefs about 
the drug. 
Positive beliefs about a drug have been shown to have positive correlations with 
compliance intentions (Lobb 2007).  Thus, weakening these beliefs may have a deleterious 
impact on the health care system.   
 
Initial Compliance Intention 
The exact path of noncompliance is complex at a minimum, and the costs are potentially 
greater than $258.3 billion (Express Scripts 2010).  Patients can deviate from the prescriber’s 
instructions either volitionally or nonvolitionally.  The deviation is volitional when the patient 
makes a conscious choice to be noncompliant with the instructions (Bentley et al. 1999).  
“[P]olypharmacy and poor patient–healthcare provider relationships (including the use of 
multiple providers) may be major determinants of nonadherence among older persons, with the 
impact of most sociodemographic factors being negligible” (Vik et al. 2004, p. 303).  Off-label 
prescribing creates another opportunity for poor communications.  In the scenarios studied, the 
linear regression revealed a direct relationship between off-label prescribing and a decrease in 
initial compliance intention.  Unlike the impact on drug beliefs, this relationship was not 
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moderated by disease criticality or other variables.  Across all scenarios, off-label use decreased 
initial compliance intentions by nearly a full point based on a nine-point scale (on-label mean = 
6.90, off-label mean = 5.97, p < 0.000). 
Given the emphasis placed on compliance, further research is needed to determine 
methods that diminish the negative impact on compliance of receiving on off-label prescription.  
Can a physician, nurse, or pharmacist simply avoid this decrease in compliance via a small 
verbal or written communication with the patient?            
 
Relevance and Reliability Judgments  
The role of relevance and reliability judgments in belief formation has been addressed in 
several studies (Sewak 2002, West et al. 2004, Jalnawala and Wilkin 2004, Lobb 2007, King and 
Wilkin 2004).  Relevance judgments have been used by patients to assess the utility of the 
information and reliability judgments to assess the dependability of pharmacists (West et al. 
2004).   
A significant positive correlation (p < 0.000) demonstrated the association between the 
physician-provided information relevance and reliability and (1) beliefs about the medication 
(Pearson’s correlation 0.510) and (2) initial compliance intention (Pearson’s correlation 0.601).  
Thus, Hypothesis 1 and Hypothesis 2 were supported.     
 
Elderly 
The elderly (≥ 65 years old) did significantly differ from the nonelderly (< 65 years old) 
on virtually all measures except trust in the FDA.  The elderly appear to be slightly more trusting 
of physicians and positive in their beliefs about drugs.  This may have supported the higher 
relevant and reliability ratings in the elderly.  Combined, these higher ratings among the elderly 
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likely led to the lower expressions of intentions of involvement in the medical decision making 
and the higher initial compliance intentions.   
These significant differences (p < 0.5) must also be interpreted cautiously.  When looking 
at the means, the greatest variation was ~0.25 on a 7-point scale or ~0.18 on a 5-point scale.  
 
Limitations 
 An online consumer panel was used as the sample frame for this study.  This panel may 
not represent the general population of the US and thus limits generalizability.  The elderly group 
was 95% Caucasian/white, which is under representative of minorities in the general US 
population.  It is important to note that while the exact percentages may not represent the 
population, the response patterns identified in this experimental design remain indicative of 
human behavior.  Given the wide use of off-label prescribing, any incremental decrease in 
compliance or trust in the physician can have significant implications for the health care system. 
 The scenarios may also not represent reality.  No studies have shown how often the FDA 
status of the drug is discussed with patients by physicians, pharmacists, or other health care 
professionals; however, these exchanges are likely taking place.  The American Cancer Society 
(2011) Web site, with a section entitled, “What questions should I ask my physician about off-
label drug use?” is evidence of these communications.  
The definition and introductory paragraphs on off-label prescribing provided to 
respondents in this study may be more effective in communicating the concepts of on- and off-
label prescribing than other available sources of information.  There are many ways to handle the 
issue that were not covered in this study, including: 
 Passing “the talk” off to another health care professional 
 Referring patients to a Web site 
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 Ignoring the issue 
 Deemphasizing it  
 Offering proactive instructions (e.g., “Don’t worry about the information that the 
pharmacist will give you with the prescription”). 
 The compliance measure in this study only dealt with initial compliance.  The duration 
and modification of impact of off-label prescribing remain unknown.  How long does the 
heightened involvement last?  In the study scenarios, patients were made aware of the off-label 
use and told that the physician uses it normally in patients like them.  What would happen if 
patients found out at the pharmacy counter that the prescribed drug was being used off-label?  
What if they discovered this at home after the prescription was filled?  Authoritative arguments 
(e.g., health care professional supportive statement of off-label use) may become less important 
over time as the patient gains experience with the product, as shown in similar research (West et 
al. 2003).   
 Only the outpatient prescription setting was modeled.  Given the large volume of 
physician-administered drugs (e.g., oncolytics), research on the impact of delivery setting may 
also yield intriguing results. 
This study only measured the physician as a source of information.  Previous studies have 
shown different relevance/reliability scores based on the source of the information (Lobb 2007).  
One can also foresee the information-seeking process differing based on criticality of the disease, 
which was also shown to affect behavior in this study. 
 The study was limited to two disease states with no expressed differences in the safety 
and efficacy of the disease-specific therapies.  One can readily see how a child’s ear infection 
may be treated differently than an elderly person’s hypertension.  This study did not attempt to 
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assess the trade-offs likely to occur in decision making with different efficacy and safety ratios. 
These factors are further complicated by financial implications associated with the payment for 
prescriptions.      
 
Future Research 
 
 Despite the common use of off-label prescribing, little is known regarding the impact on 
patient decision making.  This research has provided a base for future research to address the 
following questions: 
1. Does the decrease in trust in the physician change other behaviors? 
2. Can methods be created to overcome the decrease in trust in physicians and 
initial compliance intention?  Will they differ in effect by the health care 
professional involved?  
3. Given the difference between shown between allergies and cancer, where is the 
line drawn on disease criticality and the related impacts of off-label prescribing? 
4. How long is trust in the physician lost? 
5. How long does the patient feel compelled to be more involvement in medical 
decision making? 
6. For how may refills before off-label prescribing no longer affects compliance? 
7. How does off-label use of physician-administered products impact patient 
decision making? 
8. Do the elderly and non-elderly remain different in their behavior? 
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Conclusions 
Off-label prescribing can potentially lead to deleterious effects on patients’ health, 
including lower compliance, lower trust in physicians, and lower beliefs in the prescribed drug.  
Given how common this phenomenon is in drug prescribing (Radley et al. 2006, Peppercorn 
2008, Tarbarrok 2000, Bazzano 2009, Pathak et al. 2010), the lack of knowledge of its impact is 
alarming. 
In this study, the effects of off-label use were shown to be significant and far reaching.  
Based solely on the probability that legal paperwork will continue to increase in the health care 
setting, it is foreseeable that more patients may become aware of the approval status of their 
prescriptions.  As found in this study, only a single stimulus is required for patients to modify 
their trust in their physician, their perceived need to be involved in the health care decision 
making, their benefit and risk perceptions of their prescribed drug, and their willingness to fill 
that first prescription.  
Differences exist between the elderly and nonelderly in attitude toward off-label 
prescribing, and these differences may call for different interventions in select scenarios.  
Although more likely to express a desire to be involved in the health care decision making, the 
nonelderly segment did appear to be more open to the potential gains of using off-label drugs in 
the appropriate setting. 
As shown in previous research (Sewak 2002, West et al. 2004, Jalnawala and Wilkin 
2004, Lobb 2007, King and Wilkin 2004), judgments of the relevance/reliability of the 
information appear to filter which information is used to form beliefs about the drug and appear 
also to affect initial compliance intentions.  This study grants additional support to the Model of 
Belief_Processing.
 88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIST OF REFERENCES 
  
 89 
Ajzen, I., & Fishbein, M. (1980). Understanding attitudes and predicting social behaviour. 
Englewood Cliffs, NJ: Prentice-Hall. 
American Cancer Society. (2011). Off-label drug use. Retrieved from 
http://www.cancer.org/Treatment/TreatmentsandSideEffects/TreatmentTypes/Chemotherapy/
off-label-drug-use   
Anderson, L. A., & Dedrick, R. F. (1990).. Development of the trust in physician scale: A measure 
to assess interpersonal trust in patient-physician relationships. Psychological Reports, 67(3, 
Pt 2), 1091-1100. 
Arora,  N. K. &,McHorney, C. A. (2000). Patient preferences for medical decision making: Who 
really wants to participate? Medical Care, 38(3), 335-341. 
Bazzano, A. T. F., Mangione-Smith, R., Schonlau, M.,  Suttorp, M. J., & Brook, R. H. (2009). Off-
label prescribing to children in the United States outpatient setting..Academic Pediatrics 9(2), 
81–88. 
Beck, J. M., & Azari, E. D. (1998). FDA, off-label use, and informed consent: Debunking myths and 
misconceptions. Food & Drug Law Journal, 53(71), 1–46. 
Bentley, J. P., Wilkin, N.E., &,McCaffrey, D.J. (1999). Examining compliance from the patient’s 
perspective. Drug Topics 143(14), 58-68. 
Brosgart, C. L., Mitchell, T., Charlebois, E., Coleman, R., Mehalko, S., Young, J., & Abrams, D. 
I..(1996). Off-label drug use in human immunodeficiency virus disease. Journal of Acquired 
Immune Deficiency Syndromes & Human Retrovirology, 12(1), 56-62. 
Bruera, E., Sweeney, C., Calder, K., Palmer, L., & Benisch-Tolley, L. (2001). Patient preferences 
versus physician perceptions of treatment decisions in cancer care. Journal of Clinical 
Oncology, 19(11), 2883-2885 
Buchanan, A. E. (2000). Trust in managed care organizations. Kennedy Institute of Ethics Journal, 
10(3), 189–212. 
 
Burge, S., White, D., Bajorek, E., Bazaldua, O., Trevino, J., Albright, T.,…Cigarroa, L. (2005). 
Correlates of medication knowledge and adherence: Findings from the Residency Research 
Network of South Texas, Family Medicine, 37(10), 712-718. 
 
Chen, H., Deshpande, A. D., Jiang, R., & Martin, B. C. (2005). An epidemiological investigation of 
off-label anticonvulsant drug use in the Georgia Medicaid population. 
Pharmacoepidemiology and Drug Safety. 14(9), 629-638. 
 
Christensen, D.B. (1978). Drug-taking compliance: A review and synthesis, Health Services 
Research,13(2), 171-187. 
 
 90 
Cote, B.  (2008). Compendia: The bridge between FDA approved indications and off-label usage.  
Retrieved from  http://www.oncbiz.com/documents/OBR_0108_Compendia.pdf  
 
Davies, H. T. O., & Rundall, T. G. (2000). Managing patient trust in managed care. Milbank 
Quarterly, 78(4), 609–624. 
Denig, P., Haaijer-Ruskamp, F. M., &  Zijsling, D. H. (1988). How physicians choose drugs. Social 
Science & Medicine, 27(12), 1381–1386. 
Dugan, E., Trachtenberg, F., & Hall, M. (2004). Short forms to assess patient trust: Factor structure, 
validity, and reliability. Retrieved from 
http://academyhealth.org/files/2004/abstracts/generalposters.pdf   
Express Scripts. (2010). 2010 drug trend report.  Retrieved from http://www.express-
scripts.com/research/research/dtr/archive/2010/dtrFinal.pdf  
Fairman, K. A., & Curtiss, F. R. (2010). Regulatory actions on the off-label use of prescription 
drugs: Ongoing controversy and contradiction in 2009 and 2010. Journal of Managed Care 
Pharmacy, 16(8), 629−639. 
Food and Drug Administration.  “Off-label" and investigational use of marketed drugs, biologics, 
and medical devices - information sheet. Retrieved from   
http://www.fda.gov/RegulatoryInformation/Guidances/ucm126486.htm   
Fincham,, J.E., & Wertheimer, A.I. (1985). Using the health belief model to predict initial drug 
therapy defaulting. Social Science & Medicine, 20(1), 101-105. 
Fischer, D. G., & Fick, C. (1993). Measuring social desirability: Short forms of the Marlowe-
Crowne social desirability scale. Educational and Psychological Measurement, 53(2), 417-
424. 
Gatter, R. (2004). Faith, confidence, and health care: fostering trust in medicine through law. Wake 
Forest Law Review, 39(2), 395–445. 
General Accounting Office.  US House.  Committee on Energy and Commerce.  (2008). Federal 
oversight of food safety:  FDA’s food protection plan proposes positive first steps, but 
capacity to carry them out is critical.  Retrieved from 
http://www.gao.gov/new.items/d08435t.pdf  
General Accounting Office. (1991). Off-label drugs:  reimbursement policies constrain physicians in 
their choice of cancer therapies.  Retrieved from  http://archive.gao.gov/d18t9/144933.pdf  
 
Greenidge C. A. (2009). Patients' Trust and Distrust of Physicians: Polar or Separate 
Constructs?Ann Arbor, MI: ProQuest. 
 
 91 
Hair, J. F., Anderson, R. E., Tatham, R. L., & Black, W. C. (1998). Multivariate data analysis, Fifth 
edition. Upper Saddle River, NJ: Prentice Hall. 
 
Hall, J. A., Feldstein, M., Fretwell, M. D., Rowe, J. W., & Epstein, A. M. (1990). Older patients’ 
health status and satisfaction with medical care in an HMO population. Medical Care, 28(3), 
261-270. 
 
Hall, M. A., Dugan, E., Balkrishnan, R., & Bradley D, (2002). How disclosing HMO physician 
incentives affects trust. Health Affairs, 21(2), 197-206 
 
Hall, M. A., Zheng, B., Dugan, E., Kidd, K. E, Mishra, A, Balkrishnan, R., & Camacho, F. (2002). 
Measuring patients' trust in their primary care providers. Medical Care Research and Review, 
59(3), 293-318 
 
Hammond, S. L., & Lambert, B. L.  (1994). Communicating about medications: Directions for 
research. Health Communication, 6(4), 247-51. 
 
Harris Interactive.  (2008).  in FDA hits new low, according to WSJ.com/Harris Interactive study.  
Retrieved from  http://www.pr-inside.com/confidence-in-fda-hits-new-low-r551549.htm  
 
Harris International.  (2009). Public’s opinion of FDA shows room for improvement.  Retrieved 
from 
http://www.marketresearchworld.net/index.php?option=com_content&task=view&id=2586&
Itemid=77  
 
Harrison, J. D., Young, J. M., Butow, P., Salkeld, G., & Solomon, M. J. (2005). Is it worth the risk? 
A systematic review of instruments that measure risk propensity for use in the health setting. 
Social Science & Medicine, 60(6), 1385-1396. 
 
Ho, P. M.. Rumsfeld, J. S., Masoudi, F. A., McClure, D. L., Plomondon, M. E., Steiner, J. F., & 
Magid, D. J. (2006). Effect of medication nonadherence on hospitalization and mortality 
among patients with diabetes mellitus. Archives of Internal Medicine, 166(17),1836-1841. 
 
 
Jalnawala, N.  (2005). A study of the influence of detail-message characteristics on physicians’ 
beliefs about medications and credibility [thesis].  University, MS:  University of 
Mississippi. 
 
Jalnawala, N., & Wilkin, N. E. (2004, March). The effect of DTC ad content on belief tenacity: A 
study of appeals and argument types, 2004. Paper presented at 2004 American Pharmacists 
Association Conference, Seattle, WA.Kauffman, R. (1996, September 12). Off-Label Drug 
Use and the FDA: Review of Supplemental Drug Applications. Testimony by the American 
Academy of Pediatrics before the Subcommittee on Human Resources and the 
Intergovernmental Relations Government Reform and Oversight Committee, U.S. House of 
Representatives. Retrieved from http://www.gpo.gov/fdsys/pkg/CHRG-
104hhrg44757/pdf/CHRG-104hhrg44757.pdf   
 
 92 
Kao, A. C., Green, D. C., Zaslavsky, A. M., Koplan, J.P., & Cleary, P. D. (1998). The relationship 
between method of physician payment and patient trust. Journal of the American Medical 
Association, 280(19), 1708-1714.  
 
Keating, N. L., Gandhi, T. K, Orav, E. J., Bates, D. W., & Ayanian, J. Z. (2004).  Patient 
characteristics and experiences associated with trust in specialist physicians. Archives of 
Internal Medicine, 164(9), 1015-1020. 
 
King, S. R., & Wilkin, N. E. (2004, June). An evaluation of source credibility and information 
relevance and reliability on beliefs about weight loss supplements, 2004. Paper presented at 
2004 Drug Information Association Conference, Washington, DC. 
 
Kocs, D., & Fendrick, A. M. (2003). Effect of off-label use of oncology drugs on pharmaceutical 
costs: The rituximab experience. The American Journal of Managed Care. 9(5), 393−402. 
Kocurek, B. (2009). Promoting medication adherence in older adults . . . and the rest of us. Diabetes 
Spectrum, 22(2), 80-84 
Lake, T. (1999). Do HMOs make a difference? Consumer assessments of health care. Inquiry, 36(4), 
411–418. 
Largent, E. A., Miller, F. G., & Pearson, S. D. (2009). Going off-label without venturing off-course: 
Evidence and ethical off-label prescribing. Archives of Internal Medicine. 169(19), 
1745−1747.  
Law, J.  (2011). Investigating the line between promotion and education.  Retrieved from 
http://www.firstwordpharma.com/node/881520  
Lenk, C., Koch, P., Zappel, H., & Wiesemann, C. (2009).  Off-label, off-limits? Parental awareness 
and attitudes towards off-label use in paediatrics. European Journal of  Pediatrics,  168(12), 
1473-1478. 
Levinson, W.,  Kao, A.,  Kuby, A., & Thisted, R. A. (2005). Not all patients want to participate in 
decision making: A national study of public preferences. Journal of General Internal 
Medicine, 20(6), 531-535  
 
Lobb, W. B. (2007). Patients’ decision making in a multi-tier co-payment environment 
[dissertation].  University, MS:  University of Mississippi. 
 
Mainous, A.G., Baker, R., Love, M. M., Gray, D. P., & Gill, J. M. (2001). Continuity of care and 
trust in one’s physician: Evidence from primary care in the United States and the United 
Kingdom. Family Medicine, 33(1), 22-27. 
 
Mansell, D., Poses, R. M., Kazis, L., & Duefield, C. A. (2000). Clinical factors that influence 
patients' desire for participation in decisions about illness. Archives of Internal Medicine, 
160(19), 2991-2996.  
 93 
 
Mortenson, L.E. (1988). Audit indicates half of current chemotherapy users lack FDA approval. 
Journal of Cancer Program Management, 3, 21-26 
 
Munch, J. M., Boller, G. W., & Swasy, J. L. (1993). The effects of argument structure and affective 
tagging on product attitude formation. Journal of Consumer Research. 20(2), 294-302. 
 
National Organization for Rare Disorders. (2011). Off-label pharmaceutical use. Retreived from  
http://www.rarediseases.org/advocacy/initiatives-updates/off-label-use  
 
Osterberg, L., & Blaschke, T. (2005). Adherence to medication. The New England Journal of 
Medicine, 353(5), 487-497. 
 
Pathak, P., West, D., Martin, B .C., Helm, M. E., & Henderson, C. (2010). Evidence-based use of 
second-generation antipsychotics in a state Medicaid pediatric population, 2001—2005. 
Psychiatric Services, 61(2), 123-129. 
 
Paulhus, D. L. (1991). Measurement and control of response bias. In J. P. Robinson, P. R. Shaver, & 
L. S. Wright (Eds.), Measures of personality and social psychological attitudes (pp. 17-59). 
San Diego, CA: Academic Press.  
 
PBS Frontline. (2011).  Interview with Steven Galson, MD.  Retrieved from   
http://www.pbs.org/wgbh/pages/frontline/shows/prescription/interviews/galson.html 
 
Pearson, S. D., &  Raeke, L. H. (2000). Patients’ trust in physicians: Many theories, few measures, 
and little data. Journal of General Internal Medicine, 15(7), 509-13. 
 
Peppercorn, J., Burstein, H., Miller, F. G., Winer, E., & Joffe, S. (2008). Self-reported practices and 
attitudes of US oncologists regarding off-protocol therapy. Journal of Clinical Oncology, 
26(36), 5994−6000. 
 
Pew Research Center. (2010). Distrust, discontent, anger and partisan rancor:  the people and their 
government. Retrieved from  http://pewresearch.org/pubs/1569/trust-in-government-distrust-
discontent-anger-partisan-rancor 
 
Piette, J. D., Heisler, M., Krein, S., & Kerr, E. A. (2005). The role of patient-physician trust in 
moderating medication nonadherence due to cost pressures. Archives of Internal Medicine, 
165(15), 1749-1755. 
 
Poole, S. G., & Dooley, M. J. (2004). Off-label prescribing in oncology. Support Care Cancer,  
12(5), 302-305. 
 
Porter, A. M. W. (1969). Drug defaulting in a general medical practice. The British Medical Journal, 
1(5638), 218-222.. 
 
 94 
PricewaterhouseCoopers. (2010, November 11). Improving America’s health V.  Retrieved from 
http://www.pwc.com/us/en/health-industries/publications/improving-americas-health-v-
podcast.jhtml 
 
Radley, D. C., Finkelstein, S. N., & Stafford, R. S. (2006). Off-label prescribing among office-based 
physicians. Archives of Internal Medicine, 166(9), 1021-1026. 
   
Safran, D., Kosinski, M., Tarlov, A. R., Rogers, W. H., Taira, D. A., Lieberman, N., &Ware, J. E. 
(1998). The Primary Care Assessment Survey: Tests of data quality and measurement 
performance. Medical Care, 36(5), 728-39.  
 
Say, R., Murtagh, M., & Thomson, R. (2006). Patients' preference for involvement in medical 
decision making: A narrative review. Patient Education and Counseling, 60(2), 102-114.  
 
Sewak, S. S.  (2000). Cybermarketing of pharmaceuticals: A case for style over substance? [thesis]  
University, MS:  University of Mississippi. 
 
Sheehan, K. B. (2006). E-mail survey response rates: A review. Journal of Computer‐Mediated 
Communication, 6(2), 0-0. doi: 10.1111/j.1083-6101.2001.tb00117.x  
 
Singleton, R. A., & Straits, B. C. (1999). Approaches to Social Research.New York, NY: Oxford 
University Press. 
 
Smith, G. F., Benson, P. G., & Curley, S. P.  (1991). Belief, knowledge and uncertainty: A cognitive 
perspective on subjective probability.  Organizational Behavior and Human Decision 
Processes,48(2), 291-321. 
   
Soares, M. (2005). “Off-label” indications for oncology drug use and drug compendia: History and 
current status. Journal of Oncology Practice. 1(3), 102-105. 
 
Stafford, R. S. (2008). Regulating Off-Label Drug Use — Rethinking the Role of the FDA. The New 
England Journal of Medicine, 358(14), 1427-1429. 
 
Strahan, R., & Gerbasi, K. C.  (1972). Short, homogeneous versions of the Marlowe-Crowne social 
desirability scale.  Journal of Clinical Psychology, 28(2), 191-193. 
 
Tabarrok, A. T. (2000). Assessing the FDA via the anomaly of off-label drug prescribing. The 
Independent Review,5(1), 25- 53.  
 
Thom, D. H., & Campbell, B. (1997). Patient-physician trust: An exploratory study. Journal of 
Family Practice, 44(2), 169-76. 
 
Thom, D. H., Bloch, D. A., & Segal, E. S. (1999). An intervention to increase patients’ trust in their 
physicians. Academic Medicine, 74(2), 195-198. 
 
 95 
Thom, D. H., Hall, M. A., & Pawlson, L. G. (2004). Measuring patients’ trust in physicians when 
assessing quality of care. Health Affairs, 23(4), 124-132. 
 
Thom, D. H., Ribisl, K. M., Steward, A. L., & Luke, D. A. (1999). Validation of a measure of 
patients’ trust in their physician: The Trust in Physician Scale. Medical Care, 137(5), 510–
517. 
 
Thom, D. H. (2001). Physician behaviors that predict patient trust. The Journal of Family Practice. 
50(4), 323-328. 
 
Toulmin, S. E. (1958). The uses of argument. Cambridge, England: Cambridge University Press. 
 
Trachtenberg, F., Dugan, E., & Hall, M. A. (2005). How patients' trust relates to their involvement in 
medical care: trust in the medical profession is associated with greater willingness to seek 
care and follow recommendations. The Journal of Family Practice, 54(4), 344-352. 
 
Vik, S. A., Maxwell, C. J., & Hogan, D. B. (2004). Measurement, correlates, and health outcomes of 
medication adherence among seniors. The Annals of Pharmacotherapy, 38(2), 303-312. 
 
Wang, P. S., Bohn, R. L., Knight, E., Glynn, R. J., Mogun, H., & Avorn, J. (2002). Noncompliance 
with antihypertensive medications: the impact of depressive symptoms and psychosocial 
factors. Journal of General Internal Medicine, 17(7), 504-511. 
 
West, D. S., Wilkin, N. E., & Bentley, J. P. (2003). Role of experience and argument types in 
forming beliefs about pharmacist trustworthiness.  American Journal of Health-System 
Pharmacy, 60(11), 1136-1141.  
 
West, D., Wilkin, N., & Bentley, J. (2004). The role of information relevance and reliability in 
direct-to consumer advertising. Journal of Pharmaceutical Marketing & Management, 16(4), 
81-95. 
 
 
 
 
  
 96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 
 
  
 97 
Survey Instrument 
 
<Screening questionnaire> 
 
S1A--For patients ≥65 years of age 
 
Are you signed up as a member of a Medicare Part D plan for prescription medications? 
1. Yes 
2. No (TERMINATE) 
 
S1B---For patients <65 years of age 
 
Do you have insurance which covers prescription medication? 
1. Yes 
2. No (TERMINATE) 
 
S2. --- FOR BOTH AGE GROUPS 
Have you purchased a prescription medication at a pharmacy in the last 12 months? 
1. Yes 
2. No (TERMINATE) 
 
 
PAGE BREAK 
 
<Background on FDA> 
Please read the description below of the United States Food and Drug Administration (also 
referred to as the FDA) taken from the FDA website and describes what they do.  
“FDA is responsible for protecting the public health by assuring the safety, efficacy and security 
of human and veterinary drugs, biological products, medical devices, our nation’s food supply, 
cosmetics, and products that emit radiation. 
FDA is also responsible for advancing the public health by helping to speed innovations that 
make medicines more effective, safer, and more affordable and by helping the public get the 
accurate, science-based information they need to use medicines and foods to maintain and 
improve their health.”  
 
<FDA trust> 
 
After reading each statement, rate how much you agree or disagree with each statement 
regarding the US Food and Drug Administration.  
 
Please rate your agreement with the following statement: 
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Strongly Agree        Agree         Neutral       Disagree          Strongly Disagree 
 
1. The FDA is extremely thorough and careful.  
 
2. I completely trust the FDA’s decisions about which medical treatments are safe and 
effective. 
 
3. The FDA would never mislead me about anything. 
 
4. Sometimes the FDA cares more about what is convenient for them than about the 
patients' medical needs. 
 
5. All in all, I trust the FDA completely. 
 
6. All in all, I trust completely in the FDA’s ability to regulate prescription drugs. 
 
 
PAGE BREAK 
 
<Definition of off-label> 
 
This study will involve off-label prescribing — the prescription of a medication in a manner 
different from that approved by the FDA.  In the United States, since 1962, in order for 
prescription drugs to be allowed in the market, they must been proven safe and effective when 
treating the disease states that are listed in each drug’s label, or on label.  One previous FDA 
leader simplified the meaning of an FDA approval by saying something similar to this:   FDA 
approval means if the drug is used in the right patients, in the right way, at the right dose, then 
the benefits outweigh the risks. 
   
However, once approved by the FDA and marketed in the United States, doctors can legally rely 
on their professional judgment to use these FDA approved products to treat different diseases, 
even if those uses are not specifically approved by the FDA.  This is called off-label use.   
 
 
<Off-label attitudes> 
 
After reading each statement, rate how much you agree or disagree with each statement.  
Strongly Agree        Agree         Neutral       Disagree          Strongly Disagree 
 
1. I believe the majority of prescriptions in the US are prescribed on label to treat 
diseases for which they are FDA approved. 
 
 99 
2. I believe it is safe to use FDA approved drugs off label to treat other diseases than for 
what they were originally approved. 
 
3. I believe most physicians know when a drug is FDA approved or not approved to 
treat the disease in which they are prescribing it. 
 
4. I believe insurance companies check to make sure the drug prescribed by the 
physician is being used on label to treat a disease for which it has been FDA 
approved. 
 
5. I believe pharmacists check to make sure the drug prescribed by the physician is 
being used on label to treat a disease for which it has been FDA approved. 
 
6. I believe all of the drugs I take are on label - FDA approved for the disease in which I 
use the drugs. 
 
7. I believe drugs that are used on label - FDA approved for a disease - are always more 
effective than drugs that are used off label - FDA approved for that disease. 
 
8. I believe drugs that are on label - FDA approved for a disease are always safer than 
drugs that are off label - not FDA approved for that disease. 
 
9. I only want to be prescribed drugs that are on label - FDA approved to treat the 
specific disease I have.  
 
10. I believe doctors who prescribe drugs off label for diseases for which the drugs are 
not FDA approved are superior doctors. 
 
11. I believe doctors who prescribe drugs off label - for diseases for which the drugs are 
not FDA approved - only do so because it is the best option for their patient. 
 
12. I believe doctors only prescribe drugs off label – for diseases for which the drugs are 
not FDA approved - for very rare diseases, not for more common ones. 
 
13. For children, I believe doctors only prescribe drugs on label – for diseases for which 
the drugs are FDA approved. 
 
 
PAGE BREAK 
 
<Study> 
 
The following section is going to ask you to imagine yourself in a situation when you are sick.  
Please read the description and answer the questions as if this situation had happened to you 
personally. 
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400 respondents ≥65 targeted for Scenarios 1 - 8  (50 each) 
400 respondents <65 targeted for Scenarios 9 - 16  (50 each) 
 
<Show 1 of 8 scenarios based on 2 age groups>  
 
 
Scenario 1 (age  ≥65 / oncology / 75% on label / off label rx) 
 
Assume that you are the following patient and you are experiencing the symptoms and events 
described. Your Medicare helps cover the costs of the doctor visits and you have a Medicare Part 
D plan that helps cover the costs of medications.  After several weeks of feeling a lack of energy, 
you sought care from your primary care doctor.  After blood tests, your doctor said you need to 
go see an oncologist (a doctor that specializes in treating cancer).  Your doctor said, “This 
oncologist is a good doctor to whom I send all my patients who may have cancer.”   The 
oncologist runs several tests and informs you that you have a rare form of blood cancer that 
affects your red blood cells and explains why your energy was low.  If untreated, the cancer will 
very likely lead to death in the next year or so.  The drugs normally used to treat this cancer are 
ones that can be taken daily at home, by mouth, for roughly 6 months. 
 
The oncologist tells you national surveys show 75% of the patients in the US with this type of 
cancer receive drugs that are approved by the FDA to treat this type of cancer.  The other 25% 
receive drugs that are not approved by the FDA to treat this type of cancer. 
 
The oncologist writes you a prescription for a drug and says, “This drug is not approved by the 
FDA for this type of cancer.  However, I use this to treat all of my patients with this type of 
cancer and it has been very effective and safe.”   
 
 
Scenario 2 (age  ≥65 / oncology / 75% on label / on label rx) 
 
 
Assume that you are the following patient and you are experiencing the symptoms and events 
described. Your Medicare helps cover the costs of the doctor visits and you have a Medicare Part 
D plan that helps cover the costs of medications.  After several weeks of feeling a lack of energy, 
you sought care from your primary care doctor.  After blood tests, your doctor said you need to 
go see an oncologist (a doctor that specializes in treating cancer).  Your doctor said, “This 
oncologist is a good doctor to whom I send all my patients who may have cancer.”   The 
oncologist runs several tests and informs you that you have a rare form of blood cancer that 
affects your red blood cells and explains why your energy was low.  If untreated, the cancer will 
very likely lead to death in the next year or so.  The drugs normally used to treat this cancer are 
ones that can be taken daily at home, by mouth, for roughly 6 months. 
 
The oncologist tells you national surveys show 75% of the patients in the US with this type of 
cancer receive drugs that are approved by the FDA to treat this type of cancer.  The other 25% 
receive drugs that are not approved by the FDA to treat this type of cancer. 
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The oncologist writes you a prescription for a drug and says, “This drug is approved by the FDA 
for this type of cancer.  I use this to treat all of my patients with this type of cancer and it has 
been very effective and safe.”   
 
 
Scenario 3 (age  ≥65 / oncology / 25% on label / off label rx) 
 
Assume that you are the following patient and you are experiencing the symptoms and events 
described. Your Medicare helps cover the costs of the doctor visits and you have a Medicare Part 
D plan that helps cover the costs of medications.  After several weeks of feeling a lack of energy, 
you sought care from your primary care doctor.  After blood tests, your doctor said you need to 
go see an oncologist (a doctor that specializes in treating cancer).  Your doctor said, “This 
oncologist is a good doctor to whom I send all my patients who may have cancer.”   The 
oncologist runs several tests and informs you that you have a rare form of blood cancer that 
affects your red blood cells and explains why your energy was low.  If untreated, the cancer will 
very likely lead to death in the next year or so.  The drugs normally used to treat this cancer are 
ones that can be taken daily at home, by mouth, for roughly 6 months. 
 
The oncologist tells you national surveys show 75% of the patients in the US with this type of 
cancer receive drugs that are not approved by the FDA to treat this type of cancer.  The other 
25% receive drugs that are approved by the FDA to treat this type of cancer. 
 
The oncologist writes you a prescription for a drug and says, “This drug is not approved by the 
FDA for this type of cancer.  However, I use this to treat all of my patients with this type of 
cancer and it has been very effective and safe.”   
 
 
Scenario 4 (age  ≥65 / oncology / 25% on label / on label rx) 
 
Assume that you are the following patient and you are experiencing the symptoms and events 
described. Your Medicare helps cover the costs of the doctor visits and you have a Medicare Part 
D plan that helps cover the costs of medications.  After several weeks of feeling a lack of energy, 
you sought care from your primary care doctor.  After blood tests, your doctor said you need to 
go see an oncologist (a doctor that specializes in treating cancer).  Your doctor said, “This 
oncologist is a good doctor to whom I send all my patients who may have cancer.”   The 
oncologist runs several tests and informs you that you have a rare form of blood cancer that 
affects your red blood cells and explains why your energy was low.  If untreated, the cancer will 
very likely lead to death in the next year or so.  The drugs normally used to treat this cancer are 
ones that can be taken daily at home, by mouth, for roughly 6 months. 
 
The oncologist tells you national surveys show 75% of the patients in the US with this type of 
cancer receive drugs that are not approved by the FDA to treat this type of cancer.  The other 
25% receive drugs that are approved by the FDA to treat this type of cancer. 
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The oncologist writes you a prescription for a drug and says, “This drug is approved by the FDA 
for this type of cancer.  I use this to treat all of my patients with this type of cancer and it has 
been very effective and safe.”   
 
 
Scenario 5 (age  ≥65 / allergy / 75% on label / off label rx) 
 
Assume that you are the following patient and you are experiencing the symptoms and events 
described. Your Medicare helps cover the costs of the doctor visits and you have a Medicare Part 
D plan that helps cover the costs of medications.  After a few weeks of dealing with a runny nose 
and other small allergy issues, you sought care from your primary care doctor.  After blood tests, 
your doctor said you need to go see an allergist (a doctor that specializes in treating allergies).  
Your doctor said, “This allergist is a good doctor to whom I send all my patients with allergies.”   
The allergist runs several tests and informs you that you have a common form of allergy.  If 
untreated, the allergy will continue to bother you with a runny nose and other small allergy 
issues.  The drugs normally used to treat this allergy are ones that can be taken daily at home, by 
mouth, for roughly 6 months. 
 
The allergist tells you national surveys show 75% of the patients in the US with this type of 
allergy receive drugs that are approved by the FDA to treat this type of allergy.  The other 25% 
receive drugs that are not approved by the FDA to treat this type of allergy. 
 
The allergist writes you a prescription for a drug and says, “This drug is not approved by the 
FDA for this type of allergy.  I use this to treat all of my patients with this type of allergies and it 
has been very effective and safe.”   
 
 
Scenario 6 (age  ≥65 / allergy / 75% on label / on label rx) 
 
Assume that you are the following patient and you are experiencing the symptoms and events 
described. Your Medicare helps cover the costs of the doctor visits and you have a Medicare Part 
D plan that helps cover the costs of medications.  After a few weeks of dealing with a runny nose 
and other small allergy issues, you sought care from your primary care doctor.  After blood tests, 
your doctor said you need to go see an allergist (a doctor that specializes in treating allergies).  
Your doctor said, “This allergist is a good doctor to whom I send all my patients with allergies.”   
The allergist runs several tests and informs you that you have a common form of allergy.  If 
untreated, the allergy will continue to bother you with a runny nose and other small allergy 
issues.  The drugs normally used to treat this allergy are ones that can be taken daily at home, by 
mouth, for roughly 6 months. 
 
The allergist tells you national surveys show 75% of the patients in the US with this type of 
allergy receive drugs that are approved by the FDA to treat this type of allergy.  The other 25% 
receive drugs that are not approved by the FDA to treat this type of allergy. 
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The allergist writes you a prescription for a drug and says, “This drug is approved by the FDA 
for this type of allergy.  I use this to treat all of my patients with this type of allergy and it has 
been very effective and safe.”   
 
 
Scenario 7 (age  ≥65 / allergy / 25% on label / off label rx) 
 
Assume that you are the following patient and you are experiencing the symptoms and events 
described. Your Medicare helps cover the costs of the doctor visits and you have a Medicare Part 
D plan that helps cover the costs of medications.  After a few weeks of dealing with a runny nose 
and other small allergy issues, you sought care from your primary care doctor.  After blood tests, 
your doctor said you need to go see an allergist (a doctor that specializes in treating allergies).  
Your doctor said, “This allergist is a good doctor to whom I send all my patients with allergies.”   
The allergist runs several tests and informs you that you have a common form of allergy.  If 
untreated, the allergy will continue to bother you with a runny nose and other small allergy 
issues.  The drugs normally used to treat this allergy are ones that can be taken daily at home, by 
mouth, for roughly 6 months. 
 
The allergist tells you national surveys show 75% of the patients in the US with this type of 
allergy receive drugs that are not approved by the FDA to treat this type of allergy.  The other 
25% receive drugs that are approved by the FDA to treat this type of allergy. 
 
The allergist writes you a prescription for a drug and says, “This drug is not approved by the 
FDA for this type of allergy.  I use this to treat all of my patients with this type of allergy and it 
has been very effective and safe.”   
 
 
Scenario 8 (age  ≥65 / allergy / 25% on label / on label rx) 
 
Assume that you are the following patient and you are experiencing the symptoms and events 
described. Your Medicare helps cover the costs of the doctor visits and you have a Medicare Part 
D plan that helps cover the costs of medications.  After a few weeks of dealing with a runny nose 
and other small allergy issues, you sought care from your primary care doctor.  After blood tests, 
your doctor said you need to go see an allergist (a doctor that specializes in treating allergies).  
Your doctor said, “This allergist is a good doctor to whom I send all my patients with allergies.”   
The allergist runs several tests and informs you that you have a common form of allergy.  If 
untreated, the allergy will continue to bother you with a runny nose and other small allergy 
issues.  The drugs normally used to treat this allergy are ones that can be taken daily at home, by 
mouth, for roughly 6 months. 
 
The allergist tells you national surveys show 75% of the patients in the US with this type of 
allergy receive drugs that are not approved by the FDA to treat this type of allergy.  The other 
25% receive drugs that are approved by the FDA to treat this type of allergy. 
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The allergist writes you a prescription for a drug and says, “This drug is approved by the FDA 
for this type of allergy.  I use this to treat all of my patients with this type of allergy and it has 
been very effective and safe.”   
 
 
Scenario 9 (age  <65 / oncology / 75% on label / off label rx) 
 
Assume that you are the following patient and you are experiencing the symptoms and events 
described. Your insurance helps cover the costs of doctor visits as well as your medications.  
After several weeks of feeling a lack of energy, you sought care from your primary care doctor.  
After blood tests, your doctor said you need to go see an oncologist (a doctor that specializes in 
treating cancer).  Your doctor said, “This oncologist is a good doctor to whom I send all my 
patients that may have cancer.”   The oncologist runs several tests and informs you that you have 
a rare form of blood cancer that affects your red blood cells and explains why your energy was 
low.  If untreated, the cancer will very likely lead to death in the next year or so.  The drugs 
normally used to treat this cancer are ones that can be taken daily at home, by mouth, for roughly 
6 months. 
 
The oncologist tells you national surveys show 75% of the patients in the US with this type of 
cancer receive drugs that are approved by the FDA to treat this type of cancer.  The other 25% 
receive drugs that are not approved by the FDA to treat this type of cancer. 
 
The oncologist writes you a prescription for a drug and says, “This drug is not approved by the 
FDA for this type of cancer.  However, I use this to treat all of my patients with this type of 
cancer and it has been very effective and safe.”   
 
 
Scenario 10 (age  <65 / oncology / 75% on label / on label rx) 
 
Assume that you are the following patient and you are experiencing the symptoms and events 
described. Your insurance helps cover the costs of doctor visits as well as your medications.  
After several weeks of feeling a lack of energy, you sought care from your primary care doctor.  
After blood tests, your doctor said you need to go see an oncologist (a doctor that specializes in 
treating cancer).  Your doctor said, “This oncologist is a good doctor to whom I send all my 
patients that may have cancer.”   The oncologist runs several tests and informs you that you have 
a rare form of blood cancer that affects your red blood cells and explains why your energy was 
low.  If untreated, the cancer will very likely lead to death in the next year or so.  The drugs 
normally used to treat this cancer are ones that can be taken daily at home, by mouth, for roughly 
6 months. 
 
The oncologist tells you national surveys show 75% of the patients in the US with this type of 
cancer receive drugs that are approved by the FDA to treat this type of cancer.  The other 25% 
receive drugs that are not approved by the FDA to treat this type of cancer. 
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The oncologist writes you a prescription for a drug and says, “This drug is approved by the FDA 
for this type of cancer.  I use this to treat all of my patients with this type of cancer and it has 
been very effective and safe.”   
 
 
Scenario 11 (age  <65 / oncology / 25% on label / off label rx) 
 
Assume that you are the following patient and you are experiencing the symptoms and events 
described. Your insurance helps cover the costs of doctor visits as well as your medications.  
After several weeks of feeling a lack of energy, you sought care from your primary care doctor.  
After blood tests, your doctor said you need to go see an oncologist (a doctor that specializes in 
treating cancer).  Your doctor said, “This oncologist is a good doctor to whom I send all my 
patients that may have cancer.”   The oncologist runs several tests and informs you that you have 
a rare form of blood cancer that affects your red blood cells and explains why your energy was 
low.  If untreated, the cancer will very likely lead to death in the next year or so.  The drugs 
normally used to treat this cancer are ones that can be taken daily at home, by mouth, for roughly 
6 months. 
 
The oncologist tells you national surveys show 75% of the patients in the US with this type of 
cancer receive drugs that are not approved by the FDA to treat this type of cancer.  The other 
25% receive drugs that are approved by the FDA to treat this type of cancer. 
 
The oncologist writes you a prescription for a drug and says, “This drug is not approved by the 
FDA for this type of cancer.  However, I use this to treat all of my patients with this type of 
cancer and it has been very effective and safe.”   
 
 
Scenario 12 (age  <65 / oncology / 25% on label / on label rx) 
 
Assume that you are the following patient and you are experiencing the symptoms and events 
described. Your insurance helps cover the costs of doctor visits as well as your medications.  
After several weeks of feeling a lack of energy, you sought care from your primary care doctor.  
After blood tests, your doctor said you need to go see an oncologist (a doctor that specializes in 
treating cancer).  Your doctor said, “This oncologist is a good doctor to whom I send all my 
patients that may have cancer.”   The oncologist runs several tests and informs you that you have 
a rare form of blood cancer that affects your red blood cells and explains why your energy was 
low.  If untreated, the cancer will very likely lead to death in the next year or so.  The drugs 
normally used to treat this cancer are ones that can be taken daily at home, by mouth, for roughly 
6 months. 
 
The oncologist tells you national surveys show 75% of the patients in the US with this type of 
cancer receive drugs that are not approved by the FDA to treat this type of cancer.  The other 
25% receive drugs that are approved by the FDA to treat this type of cancer. 
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The oncologist writes you a prescription for a drug and says, “This drug is approved by the FDA 
for this type of cancer.  I use this to treat all of my patients with this type of cancer and it has 
been very effective and safe.”   
 
 
Scenario 13 (age  <65 / allergy / 75% on label / off label rx) 
 
Assume that you are the following patient and you are experiencing the symptoms and events 
described. Your insurance helps cover the costs of doctor visits as well as your medications.  
After a few weeks of dealing with a runny nose and other small allergy issues, you sought care 
from your primary care doctor.  After blood tests, your doctor said you need to go see an allergist 
(a doctor that specializes in treating allergies).  Your doctor said, “This allergist is a good doctor 
to whom I send all my patients with allergies.”   The allergist runs several tests and informs you 
that you have a common form of allergy.  If untreated, the allergy will continue to bother you 
with a runny nose and other small allergy issues.  The drugs normally used to treat this allergy 
are ones that can be taken daily at home, by mouth, for roughly 6 months. 
 
The allergist tells you national surveys show 75% of the patients in the US with this type of 
allergy receive drugs that are approved by the FDA to treat this type of allergy.  The other 25% 
receive drugs that are not approved by the FDA to treat this type of allergy. 
 
The allergist writes you a prescription for a drug and says, “This drug is not approved by the 
FDA for this type of allergy.  I use this to treat all of my patients with this type of allergy and it 
has been very effective and safe.”   
 
 
Scenario 14 (age  <65 / allergy / 75% on label / on label rx) 
 
Assume that you are the following patient and you are experiencing the symptoms and events 
described. Your insurance helps cover the costs of doctor visits as well as your medications.  
After a few weeks of dealing with a runny nose and other small allergy issues, you sought care 
from your primary care doctor.  After blood tests, your doctor said you need to go see an allergist 
(a doctor that specializes in treating allergies).  Your doctor said, “This allergist is a good doctor 
to whom I send all my patients with allergies.”   The allergist runs several tests and informs you 
that you have a common form of allergy.  If untreated, the allergy will continue to bother you 
with a runny nose and other small allergy issues.  The drugs normally used to treat this allergy 
are ones that can be taken daily at home, by mouth, for roughly 6 months. 
 
The allergist tells you national surveys show 75% of the patients in the US with this type of 
receive drugs that are approved by the FDA to treat this type of allergy.  The other 25% receive 
drugs that are not approved by the FDA to treat this type of allergy. 
 
The allergist writes you a prescription for a drug and says, “This drug is approved by the FDA 
for this type of allergy.  I use this to treat all of my patients with this type of allergy and it has 
been very effective and safe.”   
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Scenario 15 (age  <65 / allergy / 25% on label / off label rx) 
 
Assume that you are the following patient and you are experiencing the symptoms and events 
described. Your insurance helps cover the costs of doctor visits as well as your medications.  
After a few weeks of dealing with a runny nose and other small allergy issues, you sought care 
from your primary care doctor.  After blood tests, your doctor said you need to go see an allergist 
(a doctor that specializes in treating allergies).  Your doctor said, “This allergist is a good doctor 
to whom I send all my patients with allergies.”   The allergist runs several tests and informs you 
that you have a common form of allergy.  If untreated, the allergy will continue to bother you 
with a runny nose and other small allergy issues.  The drugs normally used to treat this allergy 
are ones that can be taken daily at home, by mouth, for roughly 6 months. 
 
The allergist tells you national surveys show 75% of the patients in the US with this type of 
allergy receive drugs that are not approved by the FDA to treat this type of allergy.  The other 
25% receive drugs that are approved by the FDA to treat this type of allergy. 
 
The allergist writes you a prescription for a drug and says, “This drug is not approved by the 
FDA for this type of allergy.  I use this to treat all of my patients with this type of allergy and it 
has been very effective and safe.”   
 
 
Scenario 16 (age  <65 / allergy / 25% on label / on label rx) 
 
Assume that you are the following patient and you are experiencing the symptoms and events 
described. Your insurance helps cover the costs of doctor visits as well as your medications.  
After a few weeks of dealing with a runny nose and other small allergy issues, you sought care 
from your primary care doctor.  After blood tests, your doctor said you need to go see an allergist 
(a doctor that specializes in treating allergies).  Your doctor said, “This allergist is a good doctor 
to whom I send all my patients with allergies.”   The allergist runs several tests and informs you 
that you have a common form of allergy.  If untreated, the allergy will continue to bother you 
with a runny nose and other small allergy issues.  The drugs normally used to treat this allergy 
are ones that can be taken daily at home, by mouth, for roughly 6 months. 
 
The allergist tells you national surveys show 75% of the patients in the US with this type of 
allergy receive drugs that are not approved by the FDA to treat this type of allergy.  The other 
25% receive drugs that are approved by the FDA to treat this type of allergy. 
 
The allergist writes you a prescription for a drug and says, “This drug is approved by the FDA 
for this type of allergy.  I use this to treat all of my patients with this type of allergy and it has 
been very effective and safe.”   
 
PAGE BREAK 
 
<Trust in Physicians> SCENARIOS 1-4 and 9-12  
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After reading each statement, rate how much you agree or disagree with each statement:  
 
Strongly Agree        Agree         Neutral       Disagree          Strongly Disagree 
 
1.  Sometimes this oncologist cares more about what is convenient for (him/her) than about your 
medical needs. 
 
2.     This oncologist is extremely thorough and careful. 
 
3.  You completely trust the oncologist's decisions about which medical treatments are best for 
you. 
 
4.   This oncologist is totally honest in telling you about all of the different treatment options 
available for your condition. 
 
5.     All in all, you have complete trust in this oncologist. 
 
 
 
< Trust in Physicians> SCENARIOS 5-8 and 13-16 
 
After reading each statement, rate how much you agree or disagree with each statement:  
 
Strongly Agree        Agree         Neutral       Disagree          Strongly Disagree 
 
1.  Sometimes this allergist cares more about what is convenient for (him/her) than about your 
medical needs. 
 
2.     This allergist is extremely thorough and careful. 
 
3.  You completely trust the allergist's decisions about which medical treatments are best for you. 
 
4.   This allergist is totally honest in telling you about all of the different treatment options 
available for your condition. 
 
5.     All in all, you have complete trust in this allergist. 
 
PAGE BREAK 
 
 
 
 
<Relevance and reliability> SCENARIOS 1-4 and 9-12   
 
In this scenario, I believe the information provided by the oncologist is: 
Dependable 1 2 3 4 5 6 7 8 9 Undependable 
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Helpful 1 2 3 4 5 6 7 8 9 Not helpful 
Important 1 2 3 4 5 6 7 8 9 Unimportant 
Consistent 1 2 3 4 5 6 7 8 9 Inconsistent 
Meaningful 1 2 3 4 5 6 7 8 9 Meaningless 
Relevant 1 2 3 4 5 6 7 8 9 Irrelevant 
Reliable 1 2 3 4 5 6 7 8 9 Unreliable 
Useful 1 2 3 4 5 6 7 8 9 Useless 
 
<Relevance and reliability> SCENARIOS 5-8 and 13-16 
 
In this scenario, I believe the information provided by the allergist is: 
Dependable 1 2 3 4 5 6 7 8 9 Undependable 
Helpful 1 2 3 4 5 6 7 8 9 Not helpful 
Important 1 2 3 4 5 6 7 8 9 Unimportant 
Consistent 1 2 3 4 5 6 7 8 9 Inconsistent 
Meaningful 1 2 3 4 5 6 7 8 9 Meaningless 
Relevant 1 2 3 4 5 6 7 8 9 Irrelevant 
Reliable 1 2 3 4 5 6 7 8 9 Unreliable 
Useful 1 2 3 4 5 6 7 8 9 Useless 
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<Patient involvement in medical decision making> SCENARIOS 1-4 and 9-12   
 
After reading each statement, rate how much you agree or disagree with each statement 
regarding the scenario you just read. 
 
Strongly Agree        Agree         Neutral       Disagree          Strongly Disagree 
 
 
1. I will always follow this oncologist’s recommendations about treatment.  
 
2. It is better to rely on the expert judgment of this oncologist’s than to rely on common 
sense in taking care of my own body. 
 
3. It is better to seek professional help than to try to treat myself.  
 
4. Concerning my medical care, I should take complete control 
5. Concerning my medical care, the oncologist should take complete control. 
6. In my future visits with the oncologist, I believe I will make all of the final decisions. 
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7. In my future visits with the oncologist, I believe the oncologist should take the initiative 
and decide what is best for me. 
 
 
<Patient involvement in medical decision making> SCENARIOS 5-8 and 13-16  
 
After reading each statement, rate how much you agree or disagree with each statement 
regarding the scenario you just read. 
 
Strongly Agree        Agree         Neutral       Disagree          Strongly Disagree 
 
 
1. I will always follow this allergist’s recommendations about treatment.  
 
2. It is better to rely on the expert judgment of this allergist’s than to rely on common sense 
in taking care of my own body. 
 
3. It is better to seek professional help than to try to treat myself.  
 
4. Concerning my medical care, I should take complete control 
5. Concerning my medical care, the allergist should take complete control. 
6. In my future visits with the allergist, I believe I will make all of the final decisions. 
 
7. In my future visits with the allergist, I believe the allergist should take the initiative and 
decide what is best for me. 
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< Filling the prescription>  SCENARIOS 1-4 and 9-12   
 
You take your prescription from the oncologist to the pharmacy to be filled.  The pharmacist fills 
the prescription and hands you the prescription.  The pharmacist tells you that the prescription 
copayment is similar to other prescriptions you have received in the past. 
 
I believe that the drug I have been prescribed is: 
Bad 1 2 3 4 5 6 7 Good 
Favorable 1 2 3 4 5 6 7 Unfavorable 
Harmful  1 2 3 4 5 6 7 Beneficial 
Useless 1 2 3 4 5 6 7 Useful 
Ineffective 1 2 3 4 5 6 7 Effective 
Necessary 1 2 3 4 5 6 7 Unnecessary 
Dangerous 1 2 3 4 5 6 7 Safe 
Not helpful 1 2 3 4 5 6 7 Helpful 
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Valuable 1 2 3 4 5 6 7 Not valuable 
Expensive 1 2 3 4 5 6 7 Cheap 
Worth the 
cost 
1 2 3 4 5 6 7 
Not worth the 
cost 
 
< Filling the prescription>  SCENARIOS 5-8 and 13-16 
 
You take your prescription from the allergist to the pharmacy to be filled.  The pharmacist fills 
the prescription and hands you the prescription.  The pharmacist tells you that the prescription 
copayment is similar to other prescriptions you have received in the past. 
 
I believe that the drug I have been prescribed is: 
Bad 1 2 3 4 5 6 7 Good 
Favorable 1 2 3 4 5 6 7 Unfavorable 
Harmful  1 2 3 4 5 6 7 Beneficial 
Useless 1 2 3 4 5 6 7 Useful 
Ineffective 1 2 3 4 5 6 7 Effective 
Necessary 1 2 3 4 5 6 7 Unnecessary 
Dangerous 1 2 3 4 5 6 7 Safe 
Not helpful 1 2 3 4 5 6 7 Helpful 
Valuable 1 2 3 4 5 6 7 Not valuable 
Expensive 1 2 3 4 5 6 7 Cheap 
Worth the 
cost 
1 2 3 4 5 6 7 
Not worth the 
cost 
 
 
 
 
PAGE BREAK 
 
Based on the information available in this scenario, how likely are you to purchase 
this prescribed drug? 
No chance 1 2 3 4 5 6 7 8 9 Sure to purchase 
Likely 1 2 3 4 5 6 7 8 9 Unlikely 
Not possible 1 2 3 4 5 6 7 8 9 Very possible 
Certain not to purchase 1 2 3 4 5 6 7 8 9 Certain to purchase 
 
PAGE BREAK 
 
In this scenario, I believe the FDA approval of the prescribed drug is: 
Dependable 1 2 3 4 5 6 7 8 9 Undependable 
Helpful 1 2 3 4 5 6 7 8 9 Not helpful 
Important 1 2 3 4 5 6 7 8 9 Unimportant 
Consistent 1 2 3 4 5 6 7 8 9 Inconsistent 
Meaningful 1 2 3 4 5 6 7 8 9 Meaningless 
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Relevant 1 2 3 4 5 6 7 8 9 Irrelevant 
Reliable 1 2 3 4 5 6 7 8 9 Unreliable 
Useful 1 2 3 4 5 6 7 8 9 Useless 
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What is the typical copayment you pay for a month’s supply of a drug? If unsure, please provide 
your best estimate. 
$[_|_|._|_] 
 
What would you be willing to pay for a month’s supply of this drug? 
$[_|_|._|_] 
 
PAGE BREAK 
 
<Manipulation check>  
After reading each statement, rate how much you agree or disagree with each statement:  
 
SCENARIOS 1-4 and 9-12 ONCOLOGY   
Strongly Agree        Agree         Neutral       Disagree          Strongly Disagree 
 
1. When answering these survey questions, I assume it is important to treat the cancer 
described in the scenario.  
 
2. When answering these survey questions, I assume the cancer described in the scenario 
will be extremely harmful to my health without the drug treatment.  
 
3. When answering these survey questions, I assume having the cancer described in the 
scenario will NOT have a large negative effect on my life. 
 
 
 
 
 
SCENARIOS 5-8 and 13-16 ALLERGIES 
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1. When answering these survey questions, I assume it is important to treat the allergy 
described in the scenario.  
 
2. When answering these survey questions, I assume the allergy described in the scenario 
will be extremely harmful to my health without the drug treatment.  
 
3. When answering these survey questions, I assume having the allergy described in the 
scenario will NOT have a large negative effect on my life. 
 
<Disease experience> 
Have you ever been treated for cancer? 
1. Yes 
2. No 
3. Decline to answer 
 
Have you ever been treated for allergies? 
1. Yes 
2. No 
3. Decline to answer 
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After reading each statement, rate how much you agree or disagree with each statement.  
 
Strongly 
Disagree 
1 2 3 4 5 6 7 Strongly  
Agree 
1. I always try to practice what I preach. 
 
2. There have been occasions when I took advantage of someone. 
 
3. I have never been irked when people expressed ideas very different from my own. 
 
4. At times I have really insisted on having things my own way. 
 
5. I am always willing to admit it when I make a mistake. 
 
6. I like to gossip at times. 
 
7. I never resent being asked to return a favor. 
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8. I sometimes try to get even rather than forgive and forget. 
 
9. I have never deliberately said something that hurt someone’s feelings. 
 
10. There have been occasions when I felt like smashing things. 
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<Demographics Part I> 
 
Thank you for your interest in participating in our study about your health. We will begin by 
asking you some basic classification questions that will help us to customize the survey for you. 
Please be assured that all responses will remain confidential. 
 
Are you…?  
 
1. Male 
2. Female 
 
In what year were you born? (Please enter as a four-digit number, e.g., 1970) 
[_|_|_|_] 
 
 
How many prescriptions have you purchased at the pharmacy in the past year?  
[_|_|_] 
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<Demographics Part II > 
 
What is your marital status? 
[SINGLE RESPONSE] 
 
1. Single, never married 
2. Unmarried couple living together 
3. Married 
4. Separated 
5. Divorced 
6. Widowed 
7. Decline to answer 
 
 
Including yourself, how many people live in your household? 
# people in household [_|_] 
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What is the highest level of formal education you have completed? 
[SINGLE RESPONSE] 
 
1. Some high school or less 
2. High school graduate 
3. Some college 
4. 2-year college/technical school graduate 
5. 4-year college graduate 
6. Some postgraduate work 
7. Postgraduate degree 
 
What is your race or ethnic heritage? 
[SINGLE RESPONSE] 
 
1. Black/African American 
2. Hispanic/Chicano/Latino 
3. Native American/Indian 
4. Oriental/Asian 
5. White/Caucasian 
6. Mixed race 
7. Other 
8. Decline to answer 
 
 
What is your primary religious affiliation? 
[SINGLE RESPONSE] 
 
1. Catholic 
2. Jewish 
3. Mainline Protestant 
4. Evangelical Protestant 
5. Other 
6. Not affiliated 
7. Decline to answer 
 
 
What is your employment status? 
[SINGLE RESPONSE] 
 
1. Employed full-time 
2. Employed part-time 
3. Not employed but looking for work 
4. Not employed, not looking for work 
5. Not employed, disabled 
6. Retired 
 116 
7. Student 
8. Homemaker/housewife 
9. Other  
 
 
What was your approximate total annual household income before taxes last year? 
[SINGLE RESPONSE] 
 
1. Under $15,000 
2. $15,000-$24,999 
3. $25,000-$34,999 
4. $35,000-$44,999 
5. $45,000-$74,999 
6. $75,000-$99,999 
7. $100,000-$149,999 
8. $150,000 or more 
9. Decline to answer 
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<Debrief> 
 
All of the information provided within this scenario about the diseases, percentages of off-label 
use, and drugs is fictitious.   
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